#### Check for updates

#### **OPEN ACCESS**

EDITED BY Francesco De Francesco, Marche University Hospital, Italy

#### REVIEWED BY

Armel Hervé Nwabo Kamdje, University of Garoua, Cameroon Pratima Kumari, Georgia State University, United States

\*CORRESPONDENCE Jianna Zhang, ⊠ zjnwestchina520@outlook.com

RECEIVED 09 December 2024 ACCEPTED 31 December 2024 PUBLISHED 28 January 2025

#### CITATION

Tong L, Tang L, Tang B and Zhang J (2025) Impacts of stem cells from different sources on wound healing rate in diabetic foot ulcers: a systematic review and meta-analysis. *Front. Genet.* 15:1541992. doi: 10.3389/fgene.2024.1541992

#### COPYRIGHT

© 2025 Tong, Tang, Tang and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# Impacts of stem cells from different sources on wound healing rate in diabetic foot ulcers: a systematic review and meta-analysis

# Le Tong<sup>1,2,3</sup>, Lin Tang<sup>1,2,3</sup>, Bangli Tang<sup>4</sup> and Jianna Zhang<sup>1,2,3</sup>\*

<sup>1</sup>Department of Emergency Medicine, West China Hospital, Sichuan University/West China School of Nursing, Sichuan University, Chengdu, China, <sup>2</sup>Disaster Medical Center, Sichuan University, Chengdu, China, <sup>3</sup>Nursing Key Laboratory of Sichuan Province, Chengdu, China, <sup>4</sup>Department of Dermatology, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, China

**Background:** Diabetic foot ulcers (DFU) are a significant complication of diabetes, with huge implications on patient morbidity and healthcare costs. The objective of this meta-analysis was to evaluate the impacts of stem cells from different sources on wound healing rate in DFU patients.

**Methods:** We systematically retrieved records via key databases PubMed, Cochrane Library, Web of Science, Embase, China National Knowledge Infrastructure (CNKI) and Wanfang from the inception to October 2024. The Stata 16.0 (Stata Corp, TX) software was used to perform the meta-analysis. Risk of bias in all included studies was evaluated by Cochrane Risk of Bias version 2.

Results: A total of 24 studies involving 1,321 patients were included. There was an increased likelihood of wound healing with peripheral blood-derived stem cells, the most effective cells (odds ratios (OR) = 7.31, 95% CI: 2.90-18.47), followed by adipose-derived stem cells (OR = 5.23, 95% CI: 2.76-9.90), umbilical cordderived stem cells (OR = 4.94, 95% CI: 0.61-40.03), bone-derived stem cells (OR = 4.36, 95% CI: 2.43-7.85) and other sources stem cells (OR = 3.16, 95% CI: 1.83-5.45). Nevertheless, only umbilical cord-derived stem cells showed statistical significance (p < 0.05). The heterogeneity ranged from non-existent in the adipose and peripheral blood groups ( $I^2 = 0.00\%$ ) to moderate in the bone groups ( $I^2 = 26.31\%$ ) and other groups ( $I^2 = 30.62\%$ ), and substantial in the umbilical cord groups (I<sup>2</sup> = 88.37%). Asymmetrical funnel plots pointed to publication bias, but the trim-and-fill method to correct for this brought the effect estimates even lower: based on the pooled OR, corrected OR was 3.40 (95% CI 2.39-4.84). Stem cell therapy was also associated with improvements in several secondary outcomes, suggesting its potential to influence the progression of DFU.

**Conclusion:** Our study suggested that stem cells from different sources showed potential in promoting wound healing in DFU, although with some variation in

effectiveness. Despite some publication bias and moderate heterogeneity, the overall therapeutic effect remained positive. These findings indicated that stem cell therapy might influence the progression of DFU.

KEYWORDS

stem cells, different sources, diabetic foot ulcer, wound healing rate, meta-analysis

## Introduction

Diabetic foot ulcers (DFU) refer to a condition in individuals who have been diagnosed with diabetes or have a history of the disease, characterized by infection, ulceration, or degradation of tissue in the foot. This condition frequently occurs alongside complications such as lower extremity neuropathy and/or peripheral arterial disease (Lipsky et al., 2020). Among the severe chronic complications of diabetes, DFU are particularly concerning. These ulcers adversely affect the physical health and significantly diminish the quality of life of affected individuals (Krasilnikova et al., 2022). Additionally, DFU lead to considerable psychological distress and financial strain for both the patients and their families, imposing a significant societal burden. Given its widespread impact, diabetic foot ulceration has become a critical public health issue (Edmonds et al., 2021). Statistics highlight the severity of this condition, showing that between 5% and 24% of patients with diabetic foot ulcers require amputation within 6-18 months after their initial diagnosis. Alarmingly, an amputation occurs approximately every 20 s among this population (Ibrahim, 2017). Moreover, about half of these patients die within 5 years following their amputation (Weledji and Fokam, 2014; Humphries et al., 2016).

Current therapeutic approaches for DFU include a variety of strategies: glycemic control, local wound debridement, changing wound dressings, applying antimicrobial treatments, vascular reconstruction, employing traditional Chinese medicinal compounds, hyperbaric oxygen therapy, and in severe cases, restoring lower limb blood perfusion (Singh et al., 2017; Chen et al., 2023). Despite these diverse interventions, the effectiveness of treatments for severe DFU is often limited, and some methods have inherent drawbacks. For example, extended use of high-dose antibiotics can disrupt normal bacterial balance, leading to secondary fungal infections and the development of drug-resistant bacteria (Liu et al., 2023a). Surgical options are also limited by technical challenges such as recanalization failures, vascular re-occlusions, and impaired microcirculation (Meloni et al., 2020).

Stem cell therapy holds significant promise in enhancing wound healing in DFU, largely due to its potential to regenerate tissue and modulate immune responses. Stem cells, particularly mesenchymal stem cells (MSCs), have been shown to promote wound healing by secreting growth factors and cytokines that accelerate tissue repair and reduce inflammation. For instance, studies have demonstrated that MSCs can improve angiogenesis, increase collagen synthesis, and recruit local and systemic cells involved in wound repair processes. Additionally, the immunomodulatory properties of stem cells help in mitigating the excessive inflammatory responses often seen in diabetic wounds, thereby preventing prolonged inflammation and further tissue damage (Sasaki et al., 2008; Tutuianu et al., 2021; Mimeault et al., 2007). Currently, stem cells used for the treatment of DFU are classified into autologous and allogeneic types, with primary sources including bone marrow, umbilical cord, adipose tissue, and placenta. However, the impact of stem cells from different sources on DFU healing rates has not been fully quantified (Yu et al., 2022).

This study aimed to explore the existing literature on stem cell therapies for DFU, assessing their efficacy in accelerating wound healing based on different cell sources. By providing a clearer understanding of the benefits and limitations of various stem cell therapies, this study seeked to inform clinical decision-making and highlight potential avenues for future research.

# **Methods**

We followed the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) checklist for reporting systematic reviews and meta-analysis. The study has been registered on the international prospective register of systematic reviews.

### Literature search

We conducted a thorough search to assess the association between cell therapy and ulcer healing. PubMed, Cochrane Library, Web of Science, Embase, China National Knowledge Infrastructure (CNKI) and Wanfang were searched from the inception to October 2024. The following search strategy was used: "stem cell," or "progenitor cell," or "mesenchymal stem cells," or "adipose-derived," or "bone marrow," or "peripheral blood," or "Umbilical cord," or "mononuclear cell" paired with "diabetic" paired with "foot," or "ulcer," or "wound" (Supplementary Table S1).

#### Study selection

The criteria for the inclusion of studies were pre-established as follows: 1) the study design must be either controlled clinical trials (CCTs); 2) the study population should consist of patients afflicted with diabetic foot ulcers; 3) the intervention group should have received some form of stem cells therapy, including but not limited to bone-derived stem cells, adiposederived stem cells, or peripheral blood-derived stem cells; 4) the comparison group should have received either standard care or a placebo; 5) the studies must report on the outcome measure of the wound healing rate in patients; 6) the study should have a sample size of 10 or more participants. Conversely, studies were excluded based on the following criteria: 1) studies that suffered from incomplete data with no possibility of contacting the authors for further information; 2) studies lacking a control group; 3) non-empirical studies such as letters, editorials, conference abstracts, case reports, reviews, and study protocols; 4) animal studies.

## Data extraction

Data extraction was performed by two independent reviewers utilizing standardized forms to ensure accuracy and reliability. Any discrepancies between reviewers were resolved through discussion until a consensus was achieved. The quality of the included studies was appraised based on the pre-specified inclusion criteria. The extracted data encompassed author (s), publication year, country, study design, sample size, demographic data of participants (age, gender), original ulcer size, cell source, donor type, intervention method, cell dose, follow-up time, and reported results.

## Quality assessment

The assessment of the risk of bias within the included studies was conducted independently by two reviewers using the Cochrane Collaboration's risk of bias tool (RoB 2.0). This tool facilitated a systematic evaluation across five domains of bias, namely: bias arising from the randomization process; bias due to deviations from intended interventions; bias due to missing outcome data; bias in measurement of the outcome; and bias in the selection of the reported result. Studies were then categorized based on their risk of bias as low (meeting all or at least four of the low-risk criteria), having some concerns, or high risk, to ensure a rigorous analysis of the evidence.

## Statistical analysis

Statistical analyses were performed using the random-effects model, following the DerSimonian and Laird method, to accommodate inherent between-study variability. Pooled odds ratios (OR) and mean differences (MD) with 95% confidence intervals (CI) were calculated to assess the efficacy of stem cell therapies. Heterogeneity among the included studies was quantified using the I<sup>2</sup> statistic, where values of 25%, 50%, and 75% were considered as low, moderate, and high heterogeneity, respectively. Heterogeneity was also assessed through visual inspection of L'Abbé plots. Moreover, sensitivity analysis was used to test the stability of the results, and publication bias was estimated using a funnel plot, trimand-fill analysis and Egger's and Begg's tests, with a significance threshold of P < 0.05. Subgroup analyses were conducted based on donor source, study design, and follow-up duration to explore potential sources of variability in treatment effects. All statistical analyses were performed using STATA 16.0 software. Significance was set at a p-value of less than 0.05 for all tests.

# Results

### Literature search

Initially, a comprehensive search across six databases and various registers yielded a total of 8,111 records. Of these, 337 were identified as duplicates and 7358 were automatically disqualified. Following a evaluation of titles and abstracts, 365 articles were excluded based on the inclusion and exclusion criteria. The remaining 51 full-text articles were assessed for eligibility, leading to the exclusion of an additional 98 reports due to various reasons such as non-controlled study designs, inconsistent outcomes, or because they were case reports or reviews. Ultimately, 24 studies met all inclusion criteria and were included in the qualitative synthesis of our meta-analysis (Huang et al., 2005; Zhang et al., 2007; Debin et al., 2008; Han et al., 2010; Jain et al., 2011; Lu et al., 2011; Ozturk et al., 2012; Kirana et al., 2012; You et al., 2012; Dubsky et al., 2013; Mohammadzadeh et al., 2013; Dubský et al., 2014; Lavery et al., 2014; He, 2014; Zhang et al., 2016; Park et al., 2018; Lonardi et al., 2019; Moon et al., 2019; Smith et al., 2020; Uzun et al., 2021; Liu et al., 2023b; Mrozikiewicz-Rakowska et al., 2023; Wang et al., 2024a; Wang et al., 2024b) (Figure 1).

## Characteristics of included articles

Table 1 showed the characteristics of included study. Most studies originated from Asia and Europe, with only one study from North America. Sample sizes varied widely, ranging from 12 to 167 patients, with ages between 56.6 and 64.1 years. Gender distribution differed across studies, with the total number of males slightly exceeding the total number of females. The average wound size ranged from 2.0 cm<sup>2</sup> to 23.5 cm<sup>2</sup>. Stem cell sources included bone marrow, peripheral blood, fat, umbilical cord, and other tissues, with administration methods being either injection or application. The cell doses and follow-up periods varied, with the shortest follow-up being 30 days and the longest reaching 48 months.

#### Quality assessment

A thorough quality assessment revealed that 20 studies provided detailed descriptions of the randomization methods employed. However, seven studies, despite mentioning randomization, failed to elucidate the specific methods utilized. The risk of bias was categorized as low in twelve articles, with the remaining articles falling into the medium-risk category; notably, no studies were classified as high risk (Figure 2).

## Wound healing rate by cell sources

The healing rate of wounds treated with stem cells from different sources showed obvious improvement, with peripheral blood-derived stem cells demonstrating the highest efficacy (OR = 7.31, 95% CI: 2.90–18.47). Adipose-derived stem cells were the second most effective (OR = 5.23, 95% CI: 2.76–9.90), followed by umbilical



cord-derived stem cells (OR = 4.94, 95% CI: 0.61–40.03), bone marrow-derived stem cells (OR = 4.36, 95% CI: 2.43–7.85), and stem cells from other sources (OR = 3.16, 95% CI: 1.83–5.45). The heterogeneity ranged from non-existent in the adipose and peripheral blood groups (I<sup>2</sup> = 0.00%) to moderate in the bone groups (I<sup>2</sup> = 26.31%) and other groups (I<sup>2</sup> = 30.62%), and substantial in the umbilical cord groups (I<sup>2</sup> = 88.37%). Nevertheless, only umbilical cord-derived stem cells showed statistical significance (p < 0.05) (Figure 3). The L'Abbé plot analysis shows high consistency and low heterogeneity across stem cells from different sources in promoting DFU healing, with most studies aligning closely with the equality line. However, some studies deviated, indicating that certain stem cell sources may exhibit stronger or weaker effects under specific conditions. (Supplementary Figure S1).

## **Publication bias**

In the funnel plots of studies on different sources of stem cells, only studies on bone derived stem cells showed uneven distribution, indicating potential bias (Supplementary Figure S2). The overall funnel plot shows asymmetry, indicating possible publication bias in the overall analysis (Supplementary Figure S3). Both Begg's and Egger's tests suggested the possibility of potential publication bias (P < 0.01). To address this, we performed a trim-and-fill analysis. After adjusting for the imputed studies, the pooled OR decreased from 4.40 (95% CI: 3.23–5.99) to 3.40 (95% CI: 2.39–4.84).

## Sensitivity analyses

The included literature demonstrated that excluding each study in turn had no impact on the results (Supplementary Figure S4).

## Subgroup analysis

The subgroup analysis investigated the effects of stem cell therapy on wound healing rates in diabetic foot ulcers, stratifying the data by follow-up duration, study design, and donor type (Table 2). In the group with a follow-up time of 3 months or less, peripheral blood stem cells demonstrated the most favorable therapeutic effect (OR = 7.54, 95% CI: 2.88–19.77), though it did not reach statistical significance (P > 0.05), while umbilical cord stem cell therapy had statistically significant efficacy (P < 0.05), despite higher heterogeneity (I<sup>2</sup> = 88.37%). In the group with a follow-up duration of more than 3 months, bone marrow-derived stem cells

#### TABLE 1 The baseline characteristics of the included studies.

Study	Country	Study design	Participant cases	Wo size	und (cm²)	A	ge	F/ M	Cell type	Cell source	Method	Cell dose	Follow-up duration
				E	С	E	С						
Huang et al. (2005)	China	CCT	28	2.7 ± 1.3	2.4 ± 1.2	71.1 ± 5.9	70.9 ± 6.0	10/ 18	PBMCs	Autologous	i.m.	$3 \times 10^9$ /leg	12 weeks
Zhang et al. (2007)	China	RCT	61	N	R	65 ± 7	63 ± 6	36/ 25	BMSCs	Autologous	i.m.	NR	40 days
Debin et al. (2008)	China	RCT	45	4.2 ± 1.0	3.8 ± 1.1	64.3	± 12.7	19/ 26	BMMSCs	Autologous	i.m.	$7.32\times10^8$ to 5.61 $\times$ $10^9/leg$	12 weeks
Han et al. (2010)	Italy	RCT	52	4.3 ± 2.1	4.0 ± 2.1	66.5 ± 7.5	68.4 ± 8.7	23/ 29	PLA cells	Autologous	Ad.us.ext	$>4 \times 10^6$ /ulcer	8 Weeks
Jain et al. (2011)	India	RCT	48	Ň	IR	(33,76)	(28,69)	17/ 31	BMDCs	Autologous	NA		12 weeks
Lu et al. (2011)	China	RCT	37	Ň	IR	63 ± 8	65 ± 10	22/ 15	BMMSCs/ BMMNCs	Autologous	i.m.	9.6 $\times$ 10 <sup>8</sup> /leg; 9.3 $\times$ 10 <sup>8</sup> /leg	24 Weeks
Ozturk et al. (2012)	Turkey	RCT	40	Ň	IR	71.9 ± 9.2	70.8 ± 8.8	11/ 29	PBMCs	Autologous	i.m.	$2.48 \times 10^{7}$ /leg	12 weeks
Kirana et al. (2012)	Germany	RCT	24	9.6 ± 4.2	NA	68.5 ± 1.5	70.9 ± 1.7	5/19	BMMNCs/ BMTRCs	Autologous	i.m. or i.a.	$3 \times 10^8$ /leg; $8 \times 10^7$ /leg	45 weeks
You et al. (2012)	Korea	RCT	46	4.0 ± 3.5	$5.2 \pm 6.4$	63.5 ± 9.0	62.4 ± 9.4	14/ 32	Keratinocytes	Allogenic	Dressing	NR	12 weeks
Dubsky et al. (2013)	Czech Republic	CCT	50	5.2 ± 1.6	5.9 ± 2.0	61.8 ± 9.8	63.3 ± 9.1	9/41	PBPCs/ BMMNCs	Autologous	i.m.	$2.2 \times 10^9$ /leg; $2.4 \times 10^{10}$ /leg	6 months
Mohammadzadeh et al. (2013)	Iran	RCT	21	15.8 ± 17.0	14.2 ± 4.1	63.5 ± 7.8	64.2 ± 7.8	NA	PBMSCs	Autologous	i.m.	(9.0–12.0)×10 <sup>8</sup> /leg	3 months
Dubsky et al. (2014)	Czech Republic	CCT	54	Ň	IR	62.7 ± 10.4	62.7 ± 9.1	11/ 43	BMMNCs/ PBPCs	Autologous	i.m.	NR	12 months
Lavery et al. (2014)	United States	RCT	97	3.4 ± 3.2	3.9 ± 3.2	55.5 ± 11.5	55.1 ± 12.0	29/ 68	hVWM	Allogenic	Dressing	NR	84 days
He (2014)	China	RCT	100	Ň	IR	63.3	63.2	46/ 54	HUCMSCs	Autologous	i.m.	(5.8-8.2)×10 <sup>7</sup> /leg	3 months
Zhang et al. (2016)	China	CCT	53	Ň	IR	71.3 ± 9.1	71.6 ± 9.1	26/ 27	CD133+ cells	Autologous	i.a.	$\geq 1 \times 10^7/\text{leg}$	18 months
Park et al. (2018)	Korea	RCT	167	2.8 ± 3.7	$2.4 \pm 2.7$	56.5 ± 12.7	59.3 ± 12.6	63/ 104	rhEGF	Allogenic	Spray	50 μg/mL	12 weeks

(Continued on following page)

Study	Country	Study design	Participant cases	Wo size (	und (cm²)	A	ge	F/ M	Cell type	Cell source	Method	Cell dose	Follow-up duration
				E	С	E	С						
Lonardi et al. (2019)	Italy	RCT	114	N	IR	69.0 ± 11.6	71.6 ± 10.8	28/ 86	MFAT	Autologous	i.r.w.	10-30 mL/leg	6 months
Moon et al. (2019)	Korea	RCT	39	2.0 ± 0.9	2.8 ± 2.0	59.9 ± 13.3	68.4 ± 9.9	12/ 27	ADSCs	Allogenic	Dressing	$1 \times 10^6$ cells/sheet	12 weeks
Smith et al. (2020)	United Kingdom	RCT	12	6.3 ± 2.6	$7.0 \pm 4.5$	60.2	55.2	2/10	ADSCs	Autologous	Dressing	NR	12 weeks
Uzun et al. (2021)	Turkey	RCT	20	23.5 ± 5.6	25.8 ± 5.4	57.5 ± 8.4	57.2 ± 4.5	8/12	ADSCs	Allogenic	i.m.	$6 \times 10^6$ cells/leg	48 months
Liu et al. (2023b)	China	RCT	100	N	IR	65.9 ± 6.2	64.1 ± 6.1	34/ 66	BMSCs	Autologous	i.m.	NR	30 days
Mrozikiewicz-Rakowska et al. (2023)	Poland	CCT	46	2.7 ± 2.9	2.7 ± 1.6	56.7 ± 11.1	61.7 ± 7.5	9/37	ADSCs	Allogenic	Dressing	NR	49 days
Wang et al. (2024a)	China	RCT	43	9.7 ± 4.9	10.2 ± 5.2	(	51	15/ 28	PBSCs	Autologous	i.m.	$2 \times 10^{6}$ /ulcer	12 weeks
Wang et al. (2024b)	China	RCT	86	N	IR	63.1 ±	62.8 ±	33/	UCMSCs	Allogenic	i.m.	$1 \times 10^7$ cells/sheet	5 weeks

#### TABLE 1 (Continued) The baseline characteristics of the included studies.

RCT, randomized controlled trial; CCT, clinical controlled trials; NR, no reported; PBMCs, peripheral blood mononuclear cells; i.m., intramuscular injection; i.a., intra-arterial injection; i.r.w., injected radially into wound; BMSCs, bone marrow stem cells; PLA, human processed lipoaspirate; Ad.us.ext, ad usum externum (for external use); BMMNCs, bone marrow mesenchymal stem cells; BMMNCs, bone marrow-derived mononuclear cells; PBPCs, peripheral blood progenitor cells; PBMSCs, peripheral blood mesenchymal stem cells; hVWM, human viable wound matrix; rhEGF, recombinant human epidermal growth factor; MFAT, micro-fragmented adipose tissue; ADSCs, adipose-derived stem cells; UCMSCs, umbilical cord mesenchymal stem cells.

<b>tudy ID</b> uang et al., 2005	<u>D1</u>	12	<u>D3</u>	<u>D4</u>	<u>D5</u>	Overall	•	Low risk	
hang et al., 2007								Some concerns	
Debin et al., 2008	ŏ	•					ē	High risk	
lan et al., 2010	•	•	•	•	õ				
aIn et al., 2011		•	•			•	D1	Randomisation process	
.u et al., 2011	•	•		•	•		D2	Deviations from the intend	ed interventions
zturk et al., 2012	•				•	1	D3	Missing outcome data	
Carina et al., 2012	+	•	•	•	•	•	D4	Measurement of the outcome	
You et al., 2012	•	•	•	•	•		D5	Selection of the reported	result
Dubsky et al., 2013	•	•	•	•	•				
lohammadzadeh et al., 2013	•	•		•	•	•			
Jubsky et al., 2014	•	•	•	•	•				
He et al., 2014	•	•	•	•	•				
Chang et al., 2016	•	•		•	•	•			
avery et al., 2014	•	•	•	•	•	•			
Park et al., 2018	•	•	•	•	•	•			
loon et al., 2019	•	•	•	•	•	•			
.onardi et al., 2019	•	•	•	•	•	•			
Smith et al., 2020	•	•	•	•	•	•			
Jzun et al., 2021	+	•	•	•	•	•			
.iu et al., 2023	•	•	•	•	•	•			
Irozikiewicz-Rakowska et al., 2023	•	•	•	•	•	•			
Mang X et al., 2024	•	•		•	•	•			
Vang G et al., 2024	•	•	•	•	•	•			
			Α.	Risk o	ofbias	s graph			
Overal	Bias								
Selection of the reported r	esult								
Measurement of the out	come								
Mising outcome	data							_	
Deviations from intended interven	tions								
Randomization pro	ocess								
a source of the state of the st		0		20		40		60 80	100
				20		40		55 50	100
		-						-1-	

FIGURE 2

Risk of bias summary. (A) Risk of bias graph. (B) Risk of bias summary for included studies.

showed the best the rapeutic effect (OR = 29.72, 95% CI: 5.04–175.37). Regarding study design, both CCT and RCT studies demonstrated the effectiveness of peripheral blood, bone marrow, and adipose-derived stem cells in treating diabetic foot, with higher heterogeneity observed in the RCT group. Analysis by donor type showed that allogenic stem cells, particularly adipose-

Jobo       Image of the set of the s	Adipose       Smith et al., 2020     2       Lonardi et al., 2019     44	NU	IES	No		with	05% CI	(04)
Similar et al., 2019 Here cal., 2017 Here cal., 2014 Here cal., 2015 Here cal., 2014 Here cal., 2014 Here cal., 2014 Here cal., 2015 Here cal., 2014 Here cal., 2014 Here cal., 2015 Here cal., 2014 Here cal., 2014 Here cal., 2014 Here cal., 2015 Here cal., 2014 Here cal., 2015 Here cal., 2014 Here cal., 2015 Here cal., 2015	Smith et al., 2020         2           Lonardi et al., 2019         44		100	NU		wiul	0070 01	(70)
Lonardit al., 2020 Lonardit al., 2020 Han et al., 2019 Lonardit al., 2019 Han et al., 2019 Lonardit al., 2019 Har et al., 2019 Lonardit al., 2021 Hereogeneity: $r^2 = 0.00$ , $r^2 = 0.00$ <b>Bore</b> Zhang et al., 2027 <b>Define t</b> al., 2020 <b>Define t</b> al., 2021 <b>Define t</b> al., 2012 <b>Define t</b> al., 2014 <b>Define t</b> al., 2014 <b>Define t</b> al., 2014 <b>Define t</b> al., 2014 <b>Define t</b> al., 2012 <b>Define t</b> al., 2014 <b>Define t</b> al., 2	Lonardi et al., 2019 44	4	1	5 -		2 50 [ 0	16 38 601	1 20
Lonard tot al., 2010 Han et al., 2010 Han et al., 2019 Lun et al., 2019 Lun et al., 2021 Heterogeneity: $r^2 = 0.00$ , $r^2 = 0.00\%$ , $r^2 = 1.00$ <b>Bone</b> Zhang et al., 2007 Debin et al., 2020 <b>Bone</b> Zhang et al., 2007 Lun et al., 2017 Lun et al., 2018 Lun et al., 2014 Lun et al., 2014		11	23	27		4 70 [ 1]	08 11 1 <i>1</i>	8.06
$\begin{array}{c} \text{Mon et al.} 2019 & 16 & 4 & 9 & 8 \\ \text{Mon et al.} 2019 & 16 & 4 & 9 & 8 \\ \text{Mon et al.} 2012 & 9 & 1 & 6 & 4 \\ \text{Monoxikewicz-Rakowska et al.} 2023 & 7 & 16 & 1 & 22 \\ \text{Heterogeneity:} i^{2} = 0.00; i^{2} = 0.096, \mu^{2} = 1.00 \\ \text{Test of } = 0; Q(5) = 2.37, p = 0.80 \\ \hline \textbf{Bore} \\ \hline \textbf{Zhang et al.} 2007 & 25 & 6 & 11 & 19 \\ \text{Debin et al.} 2008 & 15 & 3 & 9 & 11 \\ \text{Heterogeneity:} i^{2} = 0.00; i^{2} = 0.396, \mu^{2} = 1.00 \\ \text{Time tal.} 2023 & 22 & 28 & 13 & 37 \\ \text{Lu et al.} 2023 & 22 & 28 & 13 & 37 \\ \text{Lu et al.} 2012 & 10 & 2 & 0 & 6 \\ \text{Karina et al.} 2012 & 10 & 2 & 0 & 6 \\ \text{Karina et al.} 2012 & 10 & 2 & 0 & 6 \\ \text{Karina et al.} 2012 & 10 & 2 & 0 & 6 \\ \text{Karina et al.} 2012 & 10 & 2 & 0 & 6 \\ \text{Karina et al.} 2012 & 10 & 2 & 0 & 6 \\ \text{Karina et al.} 2012 & 10 & 2 & 0 & 6 \\ \text{Karina et al.} 2012 & 10 & 2 & 0 & 6 \\ \text{Karina et al.} 2012 & 10 & 2 & 0 & 6 \\ \text{Karina et al.} 2012 & 10 & 2 & 0 & 6 \\ \text{Karina et al.} 2012 & 10 & 2 & 0 & 6 \\ \text{Karina et al.} 2012 & 10 & 2 & 0 & 6 \\ \text{Karina et al.} 2012 & 10 & 2 & 0 & 6 \\ \text{Karina et al.} 2012 & 10 & 2 & 0 & 6 \\ \text{Test of } 0 = 0; Q(8) = 10.86, p = 0.21 \\ \hline \textbf{Others} \\ \text{You st al.} 2012 & 22 & 28 & 13 & 37 \\ \text{Lavery et al.} 2014 & 14 & 17 & 1 & 19 \\ \text{Heterogeneity; } i^{2} = 0.01, i^{2} = 0.35 \text{ W}, \mu^{2} = 1.44 \\ \text{Test of } 0 = 0; Q(2) = 2.88, p = 0.24 \\ \hline \textbf{Peripheral blood} \\ \text{Qcturk et al.} 2012 & 6 & 3 & 0 & 8 \\ \text{Moharnmadzadeh et al.} 2013 & 6 & 1 & 4 & 10 \\ \text{Huang gt al.} 205 & 14 & 4 & 7 & 11 \\ \text{Dubsky et al.} 2013 & 10 & 1 & 5 & 6 \\ \text{Huang gt al.} 205 & 14 & 4 & 7 & 11 \\ \text{Test of } 0 = 0; Q(2) = 2.48, p = 0.78 \\ \hline \textbf{Marg are tal.} 2014 & 35 & 15 & 7 & 43 \\ \text{Heterogeneity; } i^{2} = 0.01, i^{2} = 0.098, \mu^{2} = 1.24 \\ \text{Test of } 0 = 0; Q(1) = 8.00, p = 0.0 \\ \hline \textbf{Marg t at al.} 2024 & 12 & 31 & 8 & 35 \\ \hline \textbf{Moharnmadzadeh et al.} 2014 & 35 & 15 & 7 & 43 \\ \text{Heterogeneity; } i^{2} = 0.11, i^{2} = 1.548, \mu^{2} = 1.24 \\ \text{Test of } 0 = 0; Q(1) = 8.00, p = 0.0 \\ \hline \textbf{Marg t st al.} 20.41 & 8.05, p = 0.05 \\ \hline \textbf{Marg t st al.} 20.41 & 8.0$	Han et al. 2010 26	0	16	10		4.70 [ 1.	90, 11.14j 85 614.711	1.07
$\begin{array}{c} \text{Model et al., 2019} & \text{if } 0 & $	Mana et al. 2010 20	4	10	0		4 00 [ 0.	05, 014.71	1.07
Durin et al., 2021 Microsoftewicz, Packnowski et al., 2023 Heterogenety: $r^{2} = 0.00$ ; $r^{2} = 0.00\%$ , $h^{2} = 1.00$ Test of $\theta = 0; Q(5) = 2.37$ , $p = 0.80$ Bone Zhang et al., 2007 Lang et al., 2007 Lang et al., 2017 Later at al., 2017 Later at al., 2017 Test of $\theta = 0; Q(5) = 2.37$ , $p = 0.80$ Bone Zhang et al., 2008 Later at al., 2017 Later at al., 2012 Later at al., 2012 Dubsky et al., 2013 Later at al., 2012 Dubsky et al., 2014 Later at al., 2012 Later at al., 2012 Dubsky et al., 2014 Later at al., 2012 Dubsky et al., 2014 Later at al., 2012 Dubsky et al., 2013 Later at al., 2012 Dubsky et al., 2014 Later at al., 2012 Dubsky et al., 2014 Dubsky et al., 2015 Dubsky et al., 2016 Dubsky et al., 2017 Dubsky et al., 2014 Dubsky et al., 2	Moon et al., 2019 18	4	9	8		4.00 [ 0.9	95, 16.92]	3.78
$\begin{array}{c} \text{Mic2adewick2-Halowska et al., 2025} & f & 1 & 12 \\ \text{Heterogeneity:} ^{-1} = 0.00, f = 0.008, H^{-1} = 1.00 \\ \hline \text{Est of } 0 = 0; Q(5) = 2.37, p = 0.80 \\ \hline \text{Bone} \\ \hline \text{Zhang et al., 2006} & 15 & 3 & 9 & 11 \\ \hline \text{De her et al., 2008} & 15 & 3 & 9 & 11 \\ \hline \text{Jain et al., 2008} & 15 & 3 & 9 & 11 \\ \hline \text{Jain et al., 2011} & 10 & 15 & 7 & 16 \\ \hline \text{Jain et al., 2011} & 10 & 15 & 7 & 16 \\ \hline \text{Lue t al., 2021} & 10 & 2 & 0 & 6 \\ \hline \text{Karina et al., 2012} & 10 & 2 & 0 & 6 \\ \hline \text{Cubsky et al., 2013} & 11 & 4 & 17 & 4 & 19 \\ \hline \text{Lue t al., 2012} & 10 & 2 & 0 & 6 \\ \hline \text{Cubsky et al., 2013} & 14 & 4 & 17 & 4 & 19 \\ \hline \text{Heterogeneity:} ^{-1} = 0.20, f^{-2} = 26.31\%, H^{-1} = 1.36 \\ \hline \text{Heterogeneity:} ^{-1} = 0.20, f^{-2} = 26.31\%, H^{-1} = 1.36 \\ \hline \text{Heterogeneity:} ^{-1} = 0.02, f^{-2} = 26.31\%, H^{-1} = 1.44 \\ \hline \text{Ts ot } 0 = 0; Q(2) = 2.88, p = 0.24 \\ \hline \end{array}$	Uzun et al., 2021 9	1	6	4		6.00[0.	53, 57.55j	1.51
The tetrogenelity: $f = 0.00, f = 10.00 \text{ K}, H = 1.00$ Test of $\theta = 0; Q(5) = 2.37, p = 0.80$ Bone Zhang et al., 2007 Lat al., 2008 Lat al., 2008 Lat al., 2008 Lat al., 2010 Lue tal., 2023 Lue tal., 2012 Lue tal., 2014 Lue tal., 2012 Lue tal., 2014 Lue tal., 2014 Lue tal., 2014 Lue tal., 2012 Lue tal., 2014 Lue tal., 2015 Lue tal., 2014 Lue tal., 2014 Lue tal., 2015 Lue tal., 2015 Lue tal., 2015 Lue tal., 2015 Lue tal., 2014 Lue tal., 2015 Lue tal., 2014 Lue tal., 2014 Lue tal., 2014 Lue tal., 2014 Lue tal., 2015 Lue tal., 2015 Lue tal., 2015 Lue tal., 2016 Lue tal., 2017 Lue t	Mrozikiewicz-Rakowska et al., 2023 7	16	1	22		9.63[1.	U8, 86.18j	1.82
Bone Zhang et al., 2007 25 6 11 19 Label et al., 2008 15 3 9 11 Lue tal., 2003 22 28 13 37 Lue tal., 2011 10 15 7 16 All et al., 2011 10 10 7 7 16 Lue tal., 2012 10 2 0 6 Karina et al., 2012 8 4 4 0 6 Dubsy et al., 2013 14 1 3 5 6 Dubsy et al., 2014 14 17 4 19 Heterogeneity: $r^2 = 0.20$ , $r^2 = 26.31\%$ , $r^2 = 1.36$ Tart of $\theta = \theta$ : $Q(\theta) = 10.86$ , $p = 0.21$ Defined Dubsy et al., 2012 22 28 13 37 Test of $\theta = \theta$ : $Q(\theta) = 10.86$ , $p = 0.21$ Defined Dubsy et al., 2013 14 1 17 4 19 As if and a tal., 2014 14 17 4 19 As if a dat., 2014 22 28 13 37 Test of $\theta = \theta$ : $Q(\theta) = 10.86$ , $p = 0.21$ Defined Dubsy et al., 2014 22 28 13 37 Park et al., 2012 22 28 13 37 Park et al., 2013 6 0 22 43 42 As if a dat., 2014 22 28 14 3 47 Heterogeneity: $r^2 = 0.07$ , $r^2 = 30.62\%$ , $r^2 = 1.44$ Heterogeneity: $r^2 = 0.07$ , $r^2 = 30.62\%$ , $r^2 = 1.44$ Defined Dubsy et al., 2013 6 1 4 10 Manamadzadeh et al., 2013 6 1 4 10 Wang et al., 2016 3 0 3 2 As if a dat., 2024 2 13 1 14 Heterogeneity: $r^2 = 0.00$ , $r^2 = 0.00\%$ , $r^2 = 1.02$ Dubsy et al., 2015 10 1 5 6 Heterogeneity: $r^2 = 0.00$ , $r^2 = 0.00\%$ , $r^2 = 1.24$ Test of $\theta = \theta$ : $Q(t) = 2.45$ , $p = 0.78$ Dubsy et al., 2024 12 31 5 17 43 Heterogeneity: $r^2 = 0.01$ , $r^2 = 19.54\%$ , $r^2 = 1.24$ Test of $\theta = \theta$ : $Q(t) = 8.80$ , $p = 0.02$ Decine De	Heterogeneity: $\tau = 0.00$ , $I = 0.00\%$ , $H = 1.0$ Test of $\theta_i = \theta_j$ : Q(5) = 2.37, p = 0.80	00			•	5.23 [ 2.]	76, 9.90 <b>]</b>	
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Bone							
Debin et al., 2008 Jain et al., 2011 lue et al., 2023 Lue et al., 2012 Lue tal., 2011 Lue tal., 2012 Lue tal., 2013 Lue tal., 2012 Lue tal., 2013 Lue tal., 2014 Lue tal., 2013 Lue tal., 2013 Lue tal., 2014 Lue tal., 2015 Lue tal., 2015 Lue tal., 2014 Lue tal., 2014 Lu	Zhang et al., 2007 25	6	11	19		7.20 [ 2.:	26, 22.95]	5.35
Jain et al., 2011 Il u et al., 2023 Lu et al., 2023 Lu et al., 2012 Lu et al., 2014 Lu et al., 2015 Lu et al., 2014 Lu et al., 2015 Lu et al., 2014 Lu et al., 2014 Lu et al., 2014 L	Debin et al., 2008 15	3	9	11		6.11 [ 1.	34, 27.96]	3.46
liu et al., 2023 Lu et al., 2013 Lu et al., 2014 Karina et al., 2012 Dubsky et al., 2013 Dubsky et al., 2013 Heterogeneity: $r^{2} = 0.20$ , $r^{2} = 26.31\%$ , $H^{2} = 1.36$ Test of $0 = 0$ ; Q(8) = 10.86, p = 0.21 <b>Others</b> You et al., 2012 Park et al., 2012 Cut et al., 2012 Park et al., 2014 Dubsky et al., 2012 Dubsky et al., 2014 Dubsky et al., 2012 Dubsky et al., 2014 Dubsky et al., 2012 Dubsky et al., 2014 Dubsky et al., 201	Jain et al., 2011 10	15	7	16		1.52 [ 0.4	46, 5.04]	5.11
Lu et al., 2011 11 0 11 0 Karina et al., 2012 10 2 0 6 Karina et al., 2012 10 2 0 6 Karina et al., 2012 10 2 0 6 Dubsky et al., 2013 14 3 5 6 Dubsky et al., 2014 14 17 4 19 Heterogeneity: $T^2 = 0.20$ , $T^2 = 26.31\%$ , $H^2 = 1.36$ Test of $\theta = 0$ ; $Q(\theta) = 10.86$ , $p = 0.21$ <b>Others</b> You et al., 2012 2 2 28 13 37 Fark et al., 2012 2 2 28 13 37 Park et al., 2012 2 2 28 13 42 Heterogeneity: $T^2 = 0.07$ , $T^2 = 26.31\%$ , $H^2 = 1.36$ Heterogeneity: $T^2 = 0.07$ , $T^2 = 30.62\%$ , $H^2 = 1.44$ Test of $\theta = 0$ ; $Q(\theta) = 2.88$ , $p = 0.24$ <b>Peripheral blood</b> Ozturk et al., 2012 6 3 0 8 Huang et al., 2012 6 3 0 8 Huang et al., 2013 6 1 4 10 Heterogeneity: $T^2 = 0.07$ , $T^2 = 30.62\%$ , $H^2 = 1.44$ Test of $\theta = 0$ ; $Q(2) = 2.88$ , $p = 0.24$ <b>Peripheral blood</b> Ozturk et al., 2016 3 0 3 2 Hubbilical cord He et al., 2014 12 16 3 0 3 Huang et al., 2025 14 4 7 11 Dubsky et al., 2015 10 1 5 6 Heterogeneity: $T^2 = 0.07$ , $T^2 = 0.00\%$ , $H^2 = 1.00$ Test of $\theta = 0$ ; $Q(2) = 2.48$ , $p = 0.78$ <b>Umbilical cord</b> Heterogeneity: $T^2 = 2.02$ , $T^2 = 88.37\%$ , $H^2 = 1.24$ Test of $\theta = 0$ ; $Q(2) = 3.107$ , $p = 0.19$ Test of $\theta = 0$ ; $Q(2) = 3.107$ , $p = 0.19$ Test of $\theta = 0$ ; $Q(2) = 3.107$ , $p = 0.19$ Test of $\theta = 0$ ; $Q(2) = 3.107$ , $p = 0.19$ Test of $\theta = 0$ ; $Q(2) = 3.107$ , $p = 0.58$ Andom-effects DerSimonian-Laird model	liu et al., 2023 22	28	13	37	-	2.24 0.	96, 5.20]	8.31
Karina et al., 2012a Karina et al., 2012b Karina et al., 2012b Karina et al., 2013a Lasery et al., 2013a Lavery et al., 2014 Lavery et al., 2012 Colles You et al., 2012 Colles You et al., 2012 Colles Test of $0. = 0: Cl(8) = 10.86, p = 0.21$ Colles You et al., 2012 Colles Test of $0. = 0: Cl(8) = 10.86, p = 0.21$ Colles You et al., 2012 Colles Test of $0. = 0: Cl(8) = 10.86, p = 0.21$ Colles You et al., 2012 Colles Test of $0. = 0: Cl(8) = 10.86, p = 0.21$ Colles You et al., 2012 Colles Test of $0. = 0: Cl(8) = 10.86, p = 0.21$ Colles You et al., 2012 Colles Test of $0. = 0: Cl(2) = 2.88, p = 0.24$ Peripheral blood Colles Vang G et al., 2024 Colles	Lu et al., 2011 11	0	11	10		21.00 [ 1.	10, 402.20]	1.04
Karina et al., 2012b B 4 0 6 Dubsky et al., 2013a 14 3 5 6 Dubsky et al., 2013a 14 17 4 19 Heterogenetity: $r^2 = 0.20$ , $r^2 = 28.31\%$ , $H^2 = 1.36$ Test of $\theta$ , $\theta$ , $Q(\theta) = 10.86$ , $p = 0.21$ Chers You et al., 2012 22 28 13 37 Lavery et al., 2014 31 19 10 37 Park et al., 2014 30 22 43 42 Heterogenetity: $r^2 = 0.07$ , $r^2 = 30.62\%$ , $H^2 = 1.44$ Test of $\theta$ , $\theta$ ; $Q(2) = 2.88$ , $p = 0.24$ Peripheral blood Qzturk et al., 2012 6 3 0 8 Mohammadzadeh et al., 2013 6 1 4 10 Huang et al., 2024 2 13 1 14 Zhang et al., 2016 3 0 3 2 Heterogenetity: $r^2 = 0.00^2$ , $H^2 = 1.00$ Heterogenetity: $r^2 = 0.00^2$ , $H^2 = 1.00$ Test of $\theta$ , $\theta$ ; $Q(5) = 2.45$ , $p = 0.74$ Umblikal cord Het et al., 2014 35 15 7 43 Heterogenetity: $r^2 = 2.02$ , $r^2 = 88.37\%$ , $H^2 = 1.24$ Heterogenetity: $r^2 = 2.02$ , $r^2 = 88.37\%$ , $H^2 = 1.24$ Heterogenetity: $r^2 = 2.02$ , $r^2 = 88.37\%$ , $H^2 = 1.24$ Test of $\theta$ , $\theta$ ; $Q(5) = 2.45$ , $p = 0.78$ Umblikal cord Het et al., 2014 35 15 7 43 Heterogenetity: $r^2 = 2.02$ , $r^2 = 88.37\%$ , $H^2 = 1.24$ Test of $\theta$ , $\theta$ ; $Q(5) = 2.45$ , $p = 0.78$ Umblikal cord Het et al., 2014 35 15 7 43 Heterogenetity: $r^2 = 2.02$ , $r^2 = 88.37\%$ , $H^2 = 1.24$ Test of $\theta$ , $\theta$ ; $Q(5) = 2.45$ , $p = 0.78$ Umblikal cord Het et al., 2014 35 15 7 43 Heterogenetity: $r^2 = 2.02$ , $r^2 = 88.37\%$ , $H^2 = 1.24$ Test of $\theta$ , $\theta$ ; $Q(5) = 3.107$ , $p = 0.19$ Test of $\theta$ , $\theta$ ; $Q(2) = 3.107$ , $p = 0.19$ Test of $\theta$ , $\theta$ ; $Q(2) = 3.107$ , $p = 0.19$ Test of $\theta$ and $Q$ ; $Q(4) = 2.87$ , $p = 0.58$ Heterogenetity: $r^2 = 0.01$ ; $r^2 = 0.23$ , $r^2 = 0.24$ Heterogenetity: $r^2 = 0.01$ ; $r^2 = 0.24$ , $r^2 = 1.24$ Test of $\theta$ , $\theta$ ; $Q(2) = 3.107$ , $p = 0.19$ Test of $\theta$ resc (Q(2) = 3.107, $p = 0.19$ Test of group differences: $Q_4(4) = 2.87$ , $p = 0.58$ Heterogenetity: $r^2 = 0.01$ ; $r^2 = 0.23$ , $r^2 = 0.24$ Heterogenetity: $r^2 = 0.21$ , $r^2 = 0.24$ , $r^2 = 1.24$ Test of $\theta$ resc (Q(2) = 3.107, p = 0.19 Test of group differences: $Q_4(4) = 2.87$ , $p = 0.58$ Heterogenetity: $r^2 = 0$	Karina et al., 2012a 10	2	0	6		-54.60 [ 2.1	25. 1326.201	0.90
Dubsky et al., 2013a Dubsky et al., 2014 Heterogeneily: $1^{2} = 0.20$ , $1^{2} = 26.31\%$ , $H^{2} = 1.36$ Test of 0. = 0; $Q(8) = 10.86$ , $p = 0.21$ Others You et al., 2012 Park et al., 2012 Quark et al., 2014 Test of 0. = 0; $Q(2) = 2.88$ , $p = 0.24$ Peripheral blood Qzturk et al., 2012 Qzturk et al., 2012 Peripheral blood Qzturk et al., 2012 Qzturk et al., 2014 Qzturk et al., 2014 Qzturk et al., 2014 Qzturk et al., 2015 Qzturk et al., 2014 Qzturk et al., 2015 Qzturk et al., 2014 Qzturk et al., 2014 Qzturk et al., 2015 Qzturk et al., 2016 Qzturk et al., 2017 Qzturk et al., 2016 Qzturk et al., 2016 Qzturk et al., 2017 Qzturk et al., 2016 Qzturk et al., 2016 Qzturk et al., 2017 Qzturk et al., 2016 Qzturk et al., 2014 Qzturk et al., 2014 Qzturk et al., 2024 Qzturk et al., 2026 Qzturk	Karina et al., 2012b 8	4	0	6		24.56 [ 1	11. 542.411	0.95
Ducky et al., 2014 Heterogeneity: $r^{2} = 0.20$ , $l^{2} = 26.31\%$ , $H^{2} = 1.36$ Test of $\theta$ . $= \theta$ : Q(8) = 10.86, p = 0.21 Others You et al., 2012 Lavery et al., 2012 Lavery et al., 2014 Heterogeneity: $r^{2} = 0.07$ , $l^{2} = 30.62\%$ , $H^{2} = 1.34$ Test of $\theta$ . $= \theta$ : Q(2) = 2.88, p = 0.24 Peripheral blood Qzturk et al., 2012 $0 = 1.00$ , $1 = 30.62\%$ , $H^{2} = 1.44$ Test of $\theta$ . $= \theta$ : Q(2) = 2.88, p = 0.24 Peripheral blood Qzturk et al., 2016 0 = 1.2, 2016 Heterogeneity: $r^{2} = 0.00$ , $l^{2} = 0.00\%$ , $H^{2} = 1.00$ Huang et al., 2016 Heterogeneity: $r^{2} = 0.00$ , $l^{2} = 0.00\%$ , $H^{2} = 1.00$ Test of $\theta$ . $= \theta$ : Q(1) = 2.65, p = 0.78 Umbilical cord He et al., 2014 $0 = \theta$ : Q(2) = 2.87, p = 0.58 Heterogeneity: $r^{2} = 0.01$ , $l^{2} = 19.54\%$ , $H^{2} = 1.24$ Test of $\theta$ . $= \theta$ : Q(1) = 8.60, p = 0.00 Overall Heterogeneity: $r^{2} = 0.01$ , $l^{2} = 19.54\%$ , $H^{2} = 1.24$ Test of $\theta$ . $= \theta$ : Q(2) = 3.87\%, $H^{2} = 1.24$ Test of $\theta$ . $= \theta$ : Q(1) = 8.60, p = 0.00 Overall Heterogeneity: $r^{2} = 0.01$ , $l^{2} = 19.54\%$ , $H^{2} = 1.24$ Test of $\theta$ . $= \theta$ : Q(2) = 3.107, p = 0.19 Test of $\theta$ . $= \theta$ : Q(2) = 3.107, p = 0.58 Heterogeneity: $r^{2} = 0.21$ , $l^{2} = 19.54\%$ , $H^{2} = 1.24$ Test of $\theta$ . $= \theta$ : Q(2) = 3.107, p = 0.58 Heterogeneity: $r^{2} = 0.11$ , $l^{2} = 19.54\%$ , $H^{2} = 1.24$ Test of $\theta$ . $= \theta$ : Q(2) = 3.107, p = 0.58 Heterogeneity: $r^{2} = 0.21$ , $l^{2} = 19.54\%$ , $H^{2} = 1.24$ Test of $\theta$ . $= \theta$ : Q(2) = 3.107, p = 0.58 Heterogeneity: $r^{2} = 0.11$ , $l^{2} = 19.54\%$ , $H^{2} = 1.24$ Test of $\theta$ . $= \theta$ : Q(2) = 3.107, p = 0.58 Heterogeneity: $r^{2} = 0.21$ , $l^{2} = 0.58$ Heterogeneity: $r^{2} = 0.21$ , $l^{2} = 19.54\%$ , $H^{2} = 1.24$ Test of $\theta$ . $\theta$ : Q(2) = 3.107, p = 0.58 Heterogeneity: $r^{2} = 0.21$ , $l^{2} = 0.58$ Heterogeneity: $r^{2} = 0.21$ , $l^{2} =$	Dubsky et al. 2013a 14	3	5	6		5 60 [ 1	00 31 321	2.80
Because of tail, 2017 Heterogeneily: $1^{2} = 0.20$ , $1^{2} = 26.31\%$ , $H^{2} = 1.36$ Test of $0. = 0$ ; $Q(8) = 10.86$ , $p = 0.21$ Others You et al., 2012 Lavery et al., 2012 Park et al., 2018 Heterogeneily: $1^{2} = 0.07$ , $1^{2} = 30.62\%$ , $H^{2} = 1.44$ Test of $0. = 6$ ; $Q(2) = 2.88$ , $p = 0.24$ Peripheral blood Qzturk et al., 2012 Qzturk et al., 2014 Heterogeneily: $1^{2} = 0.00$ , $1^{2} = 0.00\%$ , $H^{2} = 1.04$ Pripheral blood Qzturk et al., 2016 Qzturk et al., 2017 Qzturk et al., 2018 Huang et al., 2016 Heterogeneily: $1^{2} = 0.00$ , $1^{2} = 0.00\%$ , $H^{2} = 1.00$ Test of $0. = 0$ ; $Q(1) = 2.65$ , $p = 0.78$ Umblical cord He et al., 2014 Heterogeneily: $1^{2} = 0.00$ , $1^{2} = 0.00\%$ , $H^{2} = 1.24$ Test of $0. = 0$ ; $Q(1) = 8.60$ , $p = 0.00$ Overall Heterogeneily: $1^{2} = 0.01$ , $1^{2} = 19.54\%$ , $H^{2} = 1.24$ Test of $0. = 0$ ; $Q(25) = 31.07$ , $p = 0.19$ Test of $0. = 0$ ; $Q(25) = 31.07$ , $p = 0.19$ Test of $0. = 0$ ; $Q(25) = 31.07$ , $p = 0.19$ Test of $0. = 0$ ; $Q(25) = 31.07$ , $p = 0.19$ Test of group differences: $Q_{0}(4) = 2.87$ , $p = 0.58$ Heterogeneily: $1^{2} = 0.01$ , $1^{2} = 19.54\%$ , $H^{2} = 1.24$ Test of $0. = 0$ ; $Q(25) = 31.07$ , $p = 0.19$ Test of $0. = 0$ ; $Q(25) = 31.07$ , $p = 0.19$ Test of $0. = 0$ ; $Q(25) = 31.07$ , $p = 0.19$ Test of group differences: $Q_{0}(4) = 2.87$ , $p = 0.58$ Heterogeneily: $1^{2} = 0.11$ , $1^{2} = 19.54\%$ , $H^{2} = 1.24$ Test of group differences: $Q_{0}(4) = 2.87$ , $p = 0.58$ Heterogeneily: $1^{2} = 0.11$ , $1^{2} = 19.54\%$ , $H^{2} = 1.24$ Test of group differences: $Q_{0}(4) = 2.87$ , $p = 0.58$ Heterogeneily: $1^{2} = 0.11$ , $1^{2} = 19.54\%$ , $H^{2} = 1.24$ Test of group differences: $Q_{0}(4) = 2.87$ , $p = 0.58$ Heterogeneily: $1^{2} = 0.51$ , $1^{2} = 0.51$ Heterogeneily:	Dubsky et al. 2014 14	17	1	19		3.91 [ 1.	08 14 201	4 54
Test of 0, = 0; Q(8) = 10.86, p = 0.21 Test of 0, = 0; Q(8) = 10.86, p = 0.21 Test of 0, = 0; Q(8) = 10.86, p = 0.21 To there You et al., 2012 22 28 13 37 Park et al., 2014 31 19 10 37 Park et al., 2018 60 22 43 42 Peripheral blood Qzturk et al., 2017 $f^2 = 30.62\%, H^2 = 1.44$ Test of 0, = 0; Q(2) = 2.88, p = 0.24 Peripheral blood Qzturk et al., 2017 6 3 0 8 Mohammadzadeh et al., 2013 6 1 4 10 Wang G et al., 2024 2 13 1 14 Huang et al., 2016 3 0 3 2 Huang et al., 2015 14 4 7 11 Dubsky et al., 2016 3 0 3 2 Store of 0, = 0; Q(5) = 2.45, p = 0.78 Umbilical cord He et al., 2014 35 15 7 43 Heterogeneity: $r^2 = 0.00, r^2 = 0.00\%, H^2 = 1.00$ Test of 0, = 0; Q(5) = 2.45, p = 0.78 Umbilical cord He et al., 2014 35 15 7 43 Heterogeneity: $r^2 = 2.02, r^2 = 88.37\%, H^2 = 8.60$ Test of 0, = 0; Q(5) = 2.45, p = 0.78 Umbilical cord He et al., 2014 35 15 7 43 Heterogeneity: $r^2 = 2.02, r^2 = 88.37\%, H^2 = 1.24$ Test of 0, = 0; Q(5) = 3.107, p = 0.19 Test of 0, = 0; Q(5) = 3.107, p = 0.19 Test of 0, = 0; Q(25) = 31.07, p = 0.58 Add (3.23, 5.99) Heterogeneity: $r^2 = 0.11, r^2 = 19.54\%, H^2 = 1.24$ Test of 0, = 0; Q(25) = 31.07, p = 0.58 Add (3.23, 5.99) Heterogeneity: $r^2 = 0.11, r^2 = 19.54\%, H^2 = 1.24$ Test of 0, D = 0; Q(25) = 31.07, p = 0.58 Test of 0, D = 0; Q(25) = 31.07, p = 0.58 Test of 0, D = 0; Q(25) = 2.31.07, p = 0.58 Test of 0, D = 0; Q(25) = 31.07, p = 0.58 Test of 0, D = 0; Q(25) = 31.07, p = 0.58 Test of 0, D = 0; Q(25) = 31.07, p = 0.58 Test of 0, D = 0; Q(25) = 31.07, p = 0.58 Test of 0, D = 0; Q(25) = 31.07, p = 0.58 Test of 0, D = 0; Q(25) = 31.07, p = 0.58 Test of 0, D = 0; Q(25) = 31.07, p = 0.58 Test of 0, D = 0; Q(25) = 31.07, p = 0.58 Test of 0, D = 0; Q(25) = 31.07, p = 0.58 Test of 0, D = 0; Q(25) = 31.07, p = 0.58 Test of 0, D = 0; Q(25) = 31.07, p = 0.58 Test of 0, D = 0; Q(25) = 31.07, p = 0.58 Test of 0, D = 0; Q(25) = 31.07, p = 0.58 Test of 0, D = 0; Q(25) = 31.07, p = 0.58 Test of 0, D = 0; Q(25) = 31.07, p = 0.58 Test of 0, D = 0;	Heterogeneity: $r^2 = 0.20$ $I^2 = 26.3104$ $L^2 = 4$	1 36	-	10		43612	43 7 851	4.04
Others       2.24 [ 0.96, 5.20] 8.31         You et al., 2012       22 28 13 37         Lavery et al., 2014       31 19 10 37         Park et al., 2018       60 22 43 42         Heterogeneity: $r^2 = 0.07$ , $r^2 = 30.62\%$ , $h^2 = 1.44$ Test of $\theta_1 = \theta_1$ : Q(2) = 2.88, $p = 0.24$ Peripheral blood         Qzturk et al., 2012       6 3 0 8         Mohammadzadeh et al., 2013       1 4 4 0         Jubsky et al., 2016       3 0 3 2         Heterogeneity: $r^2 = 0.00\%$ , $H^2 = 1.00$ Test of $\theta_1 = \theta_1$ : Q(1) = 2.45, $p = 0.78$ Umbilical cord         He et al., 2014       35 15 7 43         Heterogeneity: $r^2 = 0.01$ , $r^2 = 0.00\%$ , $H^2 = 1.20$ Test of $\theta_1 = \theta_1$ : Q(2) = 2.45, $p = 0.78$ Umbilical cord         He et al., 2014       35 15 7 43         Heterogeneity: $r^2 = 0.01$ , $r^2 = 19.54\%$ , $H^2 = 1.24$ Test of $\theta_1 = \theta_1$ : Q(2) = 2.45, $p = 0.78$ Ovaral       4.40 [ 3.23, 5.99]         Heterogeneity: $r^2 = 0.11$ , $r^2 = 19.54\%$ , $H^2 = 1.24$ Test of $\theta_1 = \theta_1$ : Q(2) = 31.07, $p = 0.19$ Test of $\theta_1 = \theta_2$ : Q(2) = 3.107, $p = 0.18$ Test of $\theta_1 = \theta_2$ : Q(2) = 3.107, $p = 0.18$ Test of $re = 0$ : Q(2) = 3.107, $p = 0.58$ Test	Test of $\theta_i = \theta_i$ : Q(8) = 10.86, p = 0.21	1.50				4.50 [ 2.4	43, 7.00]	
You et al., 2012 Lavery et al., 2014 Lavery et al., 2014 Park et al., 2018 Park et al., 2018 Heterogeneity: $r^2 = 0.07$ , $r^2 = 30.62\%$ , $r^2 = 1.44$ Test of $\theta_1 = \theta_1$ : Q(2) = 2.88, p = 0.24 Peripheral blood Qzturk et al., 2012 Qzturk et al., 2014 Qzturk et al., 2012 Qzturk et al., 2014 Qzturk et al., 2015 Qzturk et al., 2014 Qzturk et al., 2014 Qzturk et al., 2015 Qzturk et al., 2014 Qzturk et al., 2015 Qzturk et al., 2015 Qzturk et al., 2014 Qzturk et al., 2016 Qzturk et al., 2014 Qzturk et al., 2024 Qzturk et al., 2024	Others							
Lavery et al., 2014 Park et al., 2018 Heterogeneity: $r^2 = 0.07$ , $r^2 = 30.62\%$ , $H^2 = 1.44$ Test of $\theta_1 = \theta_1$ ; $Q(2) = 2.88$ , $p = 0.24$ Peripheral blood Qzturk et al., 2012 Qzturk et al., 2012 Qzturk et al., 2012 Qzturk et al., 2013 Qzturk et al., 2013 Qzturk et al., 2014 Qzturk et al., 2015 Qzturk et al., 2016 Qzturk et al., 2016 Qzturk et al., 2017 Qzturk et al., 2018 Qzturk et al., 2018 Qzturk et al., 2019 Qzturk et al., 2019 Qzturk et al., 2010 Qzturk et al., 2016 Qzturk et al., 2017 Quesk et al., 2018 Qzturk et al., 2014 Heterogeneity: $r^2 = 0.00$ , $r^2 = 0.00\%$ , $H^2 = 1.00$ Test of $\theta_1 = \theta_1$ : Q(1) = 8.60, $p = 0.00$ Qverall Heterogeneity: $r^2 = 0.11$ , $r^2 = 19.54\%$ , $H^2 = 1.24$ Test of $\theta_1 = \theta_1$ : Q(25) = 31.07, $p = 0.19$ Test of group differences: $Q_0(4) = 2.87$ , $p = 0.58$ Qzturk et al., 2014 Qzturk et al., 2017 Qzturk et al., 2018 Qzturk et al., 2014 Qzturk et al., 2015 Qzturk et al., 2016 Qzturk et al., 2017 Qzturk et al., 2018 Qzturk et al., 2018 Qzturk et al., 2018 Qzturk et	You et al., 2012 22	28	13	37	-	2.24 [ 0.5	96, 5.20]	8.31
Park et al., 2018 60 22 43 42 Heterogeneity: $7^2 = 0.07$ , $1^2 = 30.62\%$ , $H^2 = 1.44$ Test of $\theta_1 = \theta_1$ : Q(2) = 2.88, p = 0.24 Peripheral blood Qzturk et al., 2012 6 3 0 8 Mohammadzadeh et al., 2013 6 1 4 10 Qzturk et al., 2014 2 13 1 14 Zhang et al., 2024 2 13 1 14 Zhang et al., 2024 2 13 1 14 Zhang et al., 2015 14 4 7 11 Dubsky et al., 2013b 10 1 5 6 Heterogeneity: $7^2 = 0.00$ , $1^2 = 0.00\%$ , $H^2 = 1.00$ Test of $\theta_1 = \theta_1$ : Q(5) = 2.45, p = 0.78 Umbilical cord He et al., 2014 35 15 7 43 Wang X et al., 2024 12 31 8 35 Heterogeneity: $7^2 = 0.01$ , $1^2 = 19.54\%$ , $H^2 = 1.24$ Test of $\theta_1 = \theta_1$ : Q(2) = 31.07, p = 0.19 Test of group differences: $Q_6(4) = 2.87$ , p = 0.58 1/4 4 64 1024 Random-effects DerSimonian-Laird model	Lavery et al., 2014 31	19	10	37		6.04 [ 2.4	45, 14.88]	7.62
Heterogeneity: $r^2 = 0.07$ , $r^2 = 30.62\%$ , $H^2 = 1.44$ Test of $\theta_1 = \theta_1$ : Q(2) = 2.88, p = 0.24 Peripheral blood Qzturk et al., 2012 6 3 0 8 Mohammadzadeh et al., 2013 6 1 4 10 Wang G et al., 2024 2 13 1 14 Zhang et al., 2024 2 13 1 14 Zhang et al., 2016 3 0 3 2 Huang et al., 2016 1 4 7 11 Dubsky et al., 2015 14 4 7 11 Dubsky et al., 2013 10 1 5 6 Heterogeneity: $r^2 = 0.00$ , $r^2 = 0.00\%$ , $H^2 = 1.00$ Test of $\theta_1 = \theta_1$ : Q(1) = 2.45, p = 0.78 Umbilical cord He et al., 2024 12 31 8 35 Heterogeneity: $r^2 = 0.24$ , $r^2 = 88.37\%$ , $H^2 = 8.60$ Test of $\theta_1 = \theta_1$ : Q(1) = 8.60, p = 0.00 Overall Heterogeneity: $r^2 = 0.11$ , $r^2 = 19.54\%$ , $H^2 = 1.24$ Test of $\theta_2 = \theta_1$ : Q(25) = 31.07, p = 0.19 Test of group differences: Q <sub>b</sub> (4) = 2.87, p = 0.58 1/4 4 64 1024 Random-effects DerSimonian-Laird model	Park et al., 2018 60	22	43	42	-	2.66 [ 1.3	39. 5.091	11.15
Test of $\theta_{1} = \theta_{1}$ ; $Q(2) = 2.88$ , $p = 0.24$ Peripheral blood Qzturk et al., 2012 6 3 0 8 Mohammadzadeh et al., 2013 6 1 4 10 Wang G et al., 2024 2 13 1 14 Zhang et al., 2016 3 0 3 2 Huang et al., 2025 14 4 7 11 Dubsky et al., 2015 10 1 5 6 Huang et al., 2015 10 1 5 6 Huang et al., 2015 10 1 5 6 Huang et al., 2016 128, 23.69] 3.71 Dubsky et al., 2015 10 1 5 6 Heterogeneity: $r^{2} = 0.00$ , $r^{2} = 0.00$ %, $r^{2} = 1.00$ Test of $\theta_{1} = \theta_{1}$ ; Q(2) = 2.45, $p = 0.78$ Umbilical cord He et al., 2014 35 15 7 43 Heterogeneity: $r^{2} = 2.02$ , $r^{2} = 88.37$ %, $r^{2} = 8.60$ Test of $\theta_{1} = \theta_{1}$ ; Q(1) = 8.60, $p = 0.00$ Overall Heterogeneity: $r^{2} = 0.11$ , $r^{2} = 19.54$ %, $r^{2} = 1.24$ Test of $\theta_{1} = \theta_{1}$ ; Q(2) = 31.07, $p = 0.19$ Test of group differences: Q <sub>b</sub> (4) = 2.87, $p = 0.58$ Additional cord Heterogeneity: $r^{2} = 0.11$ , $r^{2} = 19.54$ %, $r^{2} = 1.24$ Test of $\theta_{1} = \theta_{1}$ ; Q(25) = 31.07, $p = 0.19$ Test of group differences: Q <sub>b</sub> (4) = 2.87, $p = 0.58$ Additional cord Heterogeneity: $r^{2} = 0.11$ , $r^{2} = 19.54$ %, $r^{2} = 1.24$ Test of group differences: Q <sub>b</sub> (4) = 2.87, $p = 0.58$ Additional cord Heterogeneity: $r^{2} = 0.11$ , $r^{2} = 19.54$ %, $r^{2} = 1.24$ Test of group differences: Q <sub>b</sub> (4) = 2.87, $p = 0.58$ Additional cord Heterogeneity: $r^{2} = 0.11$ , $r^{2} = 19.54$ %, $r^{2} = 1.24$ Test of group differences: Q <sub>b</sub> (4) = 2.87, $p = 0.58$ Additional cord Heterogeneity: $r^{2} = 0.11$ , $r^{2} = 19.54$ %, $r^{2} = 1.24$ Random-effects DerSimonian-Laird model	Heterogeneity: $T^2 = 0.07$ , $I^2 = 30.62\%$ , $H^2 = 1$	1.44			<b>A</b>	3.16 [ 1.	83. 5.451	
Peripheral blood         Qzturk et al., 2012       6       3       0       8       31.57 [ 1.37, 725.23 ]       0.93         Mohammadzadeh et al., 2013       6       1       4       10       15.00 [ 1.34, 167.64 ]       1.52         Wang G et al., 2024       2       13       1       14       2.15 [ 0.17, 26.67 ]       1.41         Zhang et al., 2015       14       4       7       11       5.50 [ 1.28, 23.69 ]       3.71         Dubsky et al., 2013b       10       1       5       6       7.31 [ 2.90, 18.47 ]       12.00 [ 1.12, 128.44 ]       1.57         Heterogeneity: $r^2 = 0.00$ , $r^2 = 0.00\%$ , $H^2 = 1.00$ Test of $\theta_1 = \theta_1$ ; Q(25) = 2.45, p = 0.78       14.33 [ 5.26, 39.04 ]       6.62         Wang X et al., 2024       12       31       8       35       16.9 [ 0.61, 4.68 ]       6.48         Heterogeneity: $r^2 = 2.02, r^2 = 88.37\%$ , $H^2 = 8.60$ 4.94 [ 0.61, 40.03 ]       4.40 [ 3.23, 5.99]       6.62         Wang X et al., 2024       12       31       8       35       4.40 [ 3.23, 5.99]       6.62         Heterogeneity: $r^2 = 0.11, r^2 = 19.54\%$ , $H^2 = 1.24$ Test of $\theta_1 = \theta_1$ ; Q(25) = 31.07, p = 0.19       4.40 [ 3.23, 5.99]       5.99]         Heterogeneity: $r^2 = 0.17, r^2 = 19.54\%$ , $H^2 = 1.24$	Test of $\theta_i = \theta_j$ : Q(2) = 2.88, p = 0.24				•		, ,	
Qzturk et al., 2012       6       3       0       8       31.57       [1.37, 725.23]       0.93         Mohammadzadeh et al., 2013       6       1       4       10       15.00       [1.34, 167.64]       1.52         Wang G et al., 2024       2       13       1       14       2.15       [0.17, 26.67]       1.41         Zhang et al., 2016       3       0       3       2       5.00       [0.17, 146.64]       0.80         Huang et al., 2005       14       4       7       11       5.50       [1.28, 23.69]       3.71         Dubsky et al., 2013b       10       1       5       6       7.31       [2.90, 18.47]         Test of $0 = 0;$ Q(5) = 2.45, p = 0.78       Umbilical cord       14.33       [5.26, 39.04]       6.62         Wang X et al., 2024       12       31       8       35       16.91       0.61, 4.68]       6.48         Heterogeneity: $r^2 = 2.02$ , $l^2 = 88.37\%$ , $H^2 = 8.60$ 16.91       0.61, 4.68]       6.48         Heterogeneity: $r^2 = 0.11$ , $l^2 = 19.54\%$ , $H^2 = 1.24$ 4.40       [3.23, 5.99]       5.99]         Heterogeneity: $r^2 = 0.11$ , $l^2 = 19.54\%$ , $H^2 = 1.24$ 14.44       64       1024         Test of $0_i = 0_i$ : Q(25) = 31.0	Peripheral blood							
Mohammadzadeh et al., 2013 Wang G et al., 2024 Umpilical cord He et al., 2014 Heterogeneity: $r^2 = 0.00$ , $l^2 = 0.00$ , $H^2 = 1.00$ Test of $\theta_1 = \theta_1$ : Q(5) = 2.45, p = 0.78 <b>Umpilical cord</b> He et al., 2014 Heterogeneity: $r^2 = 2.02$ , $l^2 = 88.37\%$ , $H^2 = 8.60$ Test of $\theta_1 = \theta_1$ : Q(1) = 8.60, p = 0.00 <b>Overall</b> Heterogeneity: $r^2 = 0.11$ , $l^2 = 19.54\%$ , $H^2 = 1.24$ Test of $\theta_1 = \theta_1$ : Q(25) = 31.07, p = 0.19 Test of group differences: Q <sub>b</sub> (4) = 2.87, p = 0.58 <b>A</b> andom-effects DerSimonian-Laird model	Qzturk et al., 2012 6	3	0	8		31.57 [ 1.3	37, 725.23]	0.93
Wang G et al., 2024 2 13 1 14 Zhang et al., 2016 3 0 3 2 Huang et al., 2005 14 4 7 11 Dubsky et al., 2013b 10 1 5 6 Heterogeneity: $r^2 = 0.00$ , $l^2 = 0.00\%$ , $H^2 = 1.00$ Test of $\theta_1 = \theta_1$ : Q(5) = 2.45, p = 0.78 Umbilical cord He et al., 2014 He et al., 2014 Heterogeneity: $r^2 = 2.02$ , $l^2 = 88.37\%$ , $H^2 = 8.60$ Test of $\theta_1 = \theta_2$ : Q(1) = 8.60, p = 0.00 Overall Heterogeneity: $r^2 = 0.11$ , $l^2 = 19.54\%$ , $H^2 = 1.24$ Test of $\theta_1 = \theta_2$ : Q(25) = 31.07, p = 0.19 Test of group differences: Q <sub>b</sub> (4) = 2.87, p = 0.58 Andom-effects DerSimonian-Laird model	Mohammadzadeh et al., 2013 6	1	4	10		15.00 [ 1.	34, 167.64]	1.52
Zhang et al., 2016 3 0 3 2 Huang et al., 2005 14 4 7 11 Dubsky et al., 2013b 10 1 5 6 Heterogeneity: $r^2 = 0.00$ , $l^2 = 0.00\%$ , $H^2 = 1.00$ Test of $\theta_1 = \theta_1$ : Q(5) = 2.45, p = 0.78 Umbilical cord He et al., 2014 35 15 7 43 Heterogeneity: $r^2 = 2.02$ , $l^2 = 88.37\%$ , $H^2 = 8.60$ Test of $\theta_1 = \theta_1$ : Q(1) = 8.60, p = 0.00 Overall Heterogeneity: $r^2 = 0.11$ , $l^2 = 19.54\%$ , $H^2 = 1.24$ Test of $\theta_1 = \theta_1$ : Q(25) = 31.07, p = 0.19 Test of group differences: $Q_b(4) = 2.87$ , p = 0.58 Random-effects DerSimonian-Laird model	Wang G et al., 2024 2	13	1	14 -		2.15[0.	17, 26.67]	1.41
Huang et al., 2005 Huang et al., 2013b Huerogeneity: $r^2 = 0.00$ , $l^2 = 0.00\%$ , $H^2 = 1.00$ Test of $\theta_i = \theta_i$ : Q(5) = 2.45, p = 0.78 <b>Umbilical cord</b> He et al., 2014 He et al., 2024 He et al., 2024 Heterogeneity: $r^2 = 2.02$ , $l^2 = 88.37\%$ , $H^2 = 8.60$ Test of $\theta_i = \theta_i$ : Q(1) = 8.60, p = 0.00 <b>Overali</b> Heterogeneity: $r^2 = 0.11$ , $l^2 = 19.54\%$ , $H^2 = 1.24$ Test of $\theta_i = \theta_i$ : Q(25) = 31.07, p = 0.19 Test of group differences: $Q_b(4) = 2.87$ , p = 0.58 Random-effects DerSimonian-Laird model	Zhang et al., 2016 3	0	3	2 -		5.00 [ 0.	17, 146.64]	0.80
Dubsky et al., 2013b Heterogeneity: $r^2 = 0.00$ , $l^2 = 0.00\%$ , $H^2 = 1.00$ Test of $\theta_i = \theta_i$ : Q(5) = 2.45, p = 0.78 <b>Umbilical cord</b> He et al., 2014 He et al., 2024 Heterogeneity: $r^2 = 2.02$ , $l^2 = 88.37\%$ , $H^2 = 8.60$ Test of $\theta_i = \theta_i$ : Q(1) = 8.60, p = 0.00 <b>Overali</b> Heterogeneity: $r^2 = 0.11$ , $l^2 = 19.54\%$ , $H^2 = 1.24$ Test of $\theta_i = \theta_i$ : Q(25) = 31.07, p = 0.19 Test of group differences: $Q_b(4) = 2.87$ , p = 0.58 Random-effects DerSimonian-Laird model	Huang et al., 2005 14	4	7	11		5.50 [ 1.1	28, 23.69]	3.71
Heterogeneity: $r^2 = 0.00$ , $l^2 = 0.00\%$ , $H^2 = 1.00$ Test of $\theta_i = \theta_i$ : Q(5) = 2.45, p = 0.78 <b>Umbilical cord</b> He et al., 2014 35 15 7 43 Wang X et al., 2024 12 31 8 35 Heterogeneity: $r^2 = 2.02$ , $l^2 = 88.37\%$ , $H^2 = 8.60$ Test of $\theta_i = \theta_i$ : Q(1) = 8.60, p = 0.00 <b>Overall</b> Heterogeneity: $r^2 = 0.11$ , $l^2 = 19.54\%$ , $H^2 = 1.24$ Test of $\theta_i = \theta_i$ : Q(25) = 31.07, p = 0.19 Test of group differences: $Q_b(4) = 2.87$ , p = 0.58 Random-effects DerSimonian-Laird model	Dubsky et al., 2013b 10	1	5	6		12.00 [ 1.	12, 128.84]	1.57
Umbilical cord         He et al., 2014       35       15       7       43         Wang X et al., 2024       12       31       8       35         Wang X et al., 2024       12       31       8       35         Heterogeneity: $r^2 = 2.02$ , $l^2 = 88.37\%$ , $H^2 = 8.60$ 16.9 [       0.61,       4.68]       6.48         Heterogeneity: $r^2 = 2.02$ , $l^2 = 88.37\%$ , $H^2 = 8.60$ 4.94 [       0.61,       40.03]         Test of $\theta_1 = \theta_1$ : $Q(1) = 8.60$ , $p = 0.00$ 4.40 [       3.23,       5.99]         Heterogeneity: $r^2 = 0.11$ , $l^2 = 19.54\%$ , $H^2 = 1.24$ 4.40 [       3.23,       5.99]         Heterogeneity: $r^2 = 0.11$ , $l^2 = 19.54\%$ , $H^2 = 1.24$ 11/4       4       64       1024         Test of group differences: $Q_b(4) = 2.87$ , $p = 0.58$ 11/4       4       64       1024         Random-effects DerSimonian-Laird model       11/4       4       64       1024	Heterogeneity: $r^2 = 0.00$ , $l^2 = 0.00\%$ , $H^2 = 1.0$ Test of $\theta_i = \theta_j$ : Q(5) = 2.45, p = 0.78	00			•	7.31 [ 2.	90, 18.47]	
He et al., 2014 Wang X et al., 2024 Heterogeneity: $t^2 = 2.02$ , $t^2 = 88.37\%$ , $H^2 = 8.60$ Test of $\theta_1 = \theta_1$ : Q(1) = 8.60, p = 0.00 Overall Heterogeneity: $t^2 = 0.11$ , $t^2 = 19.54\%$ , $H^2 = 1.24$ Test of $\theta_1 = \theta_1$ : Q(25) = 31.07, p = 0.19 Test of group differences: Q <sub>b</sub> (4) = 2.87, p = 0.58 Random-effects DerSimonian-Laird model	Umbilical cord							
Wang X et al., 2024       12       31       8       35       1.69 [ 0.61, 4.68]       6.48         Heterogeneity: $t^2 = 2.02$ , $t^2 = 88.37\%$ , $H^2 = 8.60$ 4.94 [ 0.61, 40.03]       4.94 [ 0.61, 40.03]       4.94 [ 0.61, 40.03]         Test of $\theta_1 = \theta_1$ : Q(1) = 8.60, p = 0.00       4.40 [ 3.23, 5.99]       4.40 [ 3.23, 5.99]         Heterogeneity: $t^2 = 0.11$ , $t^2 = 19.54\%$ , $H^2 = 1.24$ 1.40 [ 3.23, 5.99]       5.99]         Test of $\theta_1 = \theta_1$ : Q(25) = 31.07, p = 0.19       1.4       64       1024         Random-effects DerSimonian-Laird model       1/4       4       64       1024	He et al., 2014 35	15	7	43		14.33 [ 5.:	26, 39.04]	6.62
Heterogeneity: $t^2 = 2.02$ , $t^2 = 88.37\%$ , $H^2 = 8.60$ Test of $\theta_1 = \theta_1$ : Q(1) = 8.60, p = 0.00 <b>Overall</b> Heterogeneity: $t^2 = 0.11$ , $t^2 = 19.54\%$ , $H^2 = 1.24$ Test of $\theta_1 = \theta_1$ : Q(25) = 31.07, p = 0.19 Test of group differences: Q <sub>b</sub> (4) = 2.87, p = 0.58 Random-effects DerSimonian-Laird model	Wang X et al., 2024 12	31	8	35		1.69 [ 0.	61, 4.68]	6.48
Test of $\theta_i = \theta_i$ : Q(1) = 8.60, p = 0.00 <b>Overall</b> Heterogeneity: $t^2 = 0.11$ , $l^2 = 19.54\%$ , $H^2 = 1.24$ Test of $\theta_i = \theta_i$ : Q(25) = 31.07, p = 0.19 Test of group differences: Q <sub>b</sub> (4) = 2.87, p = 0.58 1/4 4 64 1024 Random-effects DerSimonian-Laird model	Heterogeneity: $\tau^2 = 2.02$ , $I^2 = 88.37\%$ , $H^2 = 8$	3.60				4.94 [ 0.	61, 40.03]	
Overall $4.40 [ 3.23, 5.99]$ Heterogeneity: $\tau^2 = 0.11, l^2 = 19.54\%, H^2 = 1.24$ $4.40 [ 3.23, 5.99]$ Test of $\theta_1 = \theta_1$ : Q(25) = 31.07, p = 0.19 $1.44 = 1.24$ Test of group differences: $Q_b(4) = 2.87, p = 0.58$ $1.44 = 1.24$ Random-effects DerSimonian-Laird model $1.44 = 64 = 1.024$	Test of $\theta_i = \theta_i$ : Q(1) = 8.60, p = 0.00							
Heterogeneity: $r^2 = 0.11$ , $l^2 = 19.54\%$ , $H^2 = 1.24$ Test of $\theta_i = \theta_i$ : Q(25) = 31.07, p = 0.19 Test of group differences: Q <sub>b</sub> (4) = 2.87, p = 0.58 1/4 4 64 1024 Random-effects DerSimonian-Laird model					•	4.40 [ 3.:	23, 5.99]	
Test of group differences: $Q_b(4) = 2.87$ , p = 0.58 1/4 4 64 1024 Random-effects DerSimonian-Laird model	Overall							
1/4 4 64 1024 Random-effects DerSimonian-Laird model	<b>Overall</b> Heterogeneity: $\tau^2 = 0.11$ , $I^2 = 19.54\%$ , $H^2 = 1$ Test of $\theta_i = \theta_i$ : Q(25) = 31.07, p = 0.19	1.24						
r	<b>Overall</b> Heterogeneity: $\tau^2 = 0.11$ , $I^2 = 19.54\%$ , $H^2 = 1$ Test of $\theta_1 = \theta_1$ : Q(25) = 31.07, p = 0.19 Test of group differences: Q <sub>b</sub> (4) = 2.87, p = 0	1.24 ).58		-		-		
	<b>Overall</b> Heterogeneity: $\tau^2 = 0.11$ , $I^2 = 19.54\%$ , $H^2 = 1$ Test of $\theta_1 = \theta_1$ : Q(25) = 31.07, p = 0.19 Test of group differences: Q <sub>b</sub> (4) = 2.87, p = 0 Random-effects DerSimonian-Laird model	1.24 ).58		- 1	/4 4 64 10	- 24		

derived stem cells (OR = 5.36, 95% CI: 1.82-15.77), also had favorable therapeutic effects for diabetic foot. In autologous stem cell group, peripheral blood-derived stem cells demonstrated the most favorable therapeutic effect compared to bone-derived and adipose-derived stem cells (OR = 7.31, 95% CI: 2.90-18.47).

# Secondary outcomes

Seven studies reported healing time, highlighting 13.44 days shorter of the trial group than the control one (95% CI –22.76 to –4.13, P < 0.01). Among them, patients treated

TABLE 2 The results of subgroup analysis.

	n	Odds ratio	95% CI	I², %	P value
Follow-up durat	tion				
Less than or eq	ual to	o 3 months			
Peripheral blood	5	7.54	2.88-19.77	0.00	0.66
Bone	6	3.36	2.03-5.53	4.17	0.39
Adipose	3	4.63	1.54-13.94	0.00	0.72
Umbilical cord	2	4.94	0.61-40.03	88.37	<0.05
Others	3	3.16	1.83-5.45	30.62	0.24
More than 3 m	onths				
Peripheral blood	1	5.00	0.17-146.64	_	_
Bone	3	29.72	5.04-175.37	0.00	0.90
Adipose	3	5.56	2.54-12.17	0.00	0.44
Study design					
ССТ					
Peripheral blood	1	12.00	1.12-128.84	_	_
Bone	2	4.45	1.59-12.49	0.00	0.74
Adipose	1	9.63	1.08-86.18	_	—
RCT					
Peripheral blood	5	7.99	1.99-32.01	0.00	0.55
Bone	7	4.82	2.17-10.70	43.74	0.10
Adipose	5	4.94	2.53-9.63	0.00	0.73
Umbilical cord	2	4.94	0.61-40.03	88.37	<0.05
Others	3	3.16	1.83-5.45	30.62	0.24
Donor type					
Allogenic					
Adipose	3	5.36	1.82-15.77	0.00	0.80
Others	3	3.16	1.83-5.45	30.62	0.24
Umbilical cord	2	4.94	0.61-40.03	88.37	<0.05
Autologous					
Peripheral blood	6	7.31	2.90-18.47	0.00	0.78
Bone	9	4.36	2.43-7.85	26.31	0.21
Adipose	3	5.16	2.34-11.39	0.00	0.38

RCT, randomized controlled trial; CCT, clinical controlled trials.

with stem cells from other sources had significantly shorter ulcer healing times compared to those treated with bone marrow, adipose tissue, or umbilical cord stem cells. However, the results for ulcer healing time showed considerable heterogeneity ( $I^2 = 99.06\%$ ), but the overall result was statistically significant (Figure 4). Regarding ankle brachial index (ABI), the results showed a slight improvement (MD = 0.10, 95% CI: 0.05–0.15), but did not reach statistical significance (P > 0.05) (Figure 5). Although the results for amputation rate also did not reach statistical significance (P > 0.05), all stem cell sources demonstrated consistent positive effects (OR = 0.22, 95% CI: 0.12-0.42) (Figure 6).

## Discussion

This study assessed the efficacy of various stem cell therapies in promoting ulcer healing in patients with DFU. The efficacy varied across different stem cell sources, with peripheral bloodderived cells demonstrating the most potent effect, while adipose-derived, umbilical cord-derived, bone marrow-derived, and other source stem cells also contributed to improved ulcer healing. Heterogeneity across the studies was relatively moderate, suggesting a reasonable consistency among the included studies despite the varied therapeutic outcomes. However, publication bias, as indicated by funnel plot asymmetry and confirmed through the trim-and-fill method, suggested an initial overestimation of treatment effects. Subgroup analysis revealed that treatment outcomes were influenced by follow-up duration, study design, and donor type, although no significant statistical differences were found between the groups except for umbilical cord derived stem cells. Additionally, stem cell therapy demonstrated positive clinical effects in accelerating wound healing, improving ABI, and reducing amputation rates, further highlighting its potential in the management of diabetic foot ulcers.

In recent years, numerous studies have explored the potential efficacy of stem cells in treating diabetic foot ulcers, examining their specific molecular mechanisms, types, and expanded applications, with the goal of advancing the clinical use of stem cell therapy for DFU (Galindo et al., 2011; Xia et al., 2024). Previous studies demonstrated a superior therapeutic impact of cellular interventions, assessing not only therapeutic efficacy but also the critical outcome of amputation rates, although the studies were limited by small sample sizes and a lack of variability in outcome measures (Guo et al., 2017; Dai et al., 2020). More recently, Sun et al., in 2022 analyzed fourteen studies with a total of 683 participants, revealing that cell-based therapy improved several outcomes including wound healing rates, vascular neogenesis in the lower extremities, TcPO2, ABI values, and pain-free walking distances. Additionally, these interventions were linked to reduced amputation rates and resting pain scores. These results are consistent with those of the current study, particularly in terms of vascular neogenesis and improvements in pain management and mobility. However, significant gaps remain in the research on TcPO2, pain-free ambulation, and rest-induced pain, highlighting the need for more comprehensive studies. The analysis also pointed out the lack of subgroup analyses that could differentiate the effects of various cellular therapies, adding a layer of uncertainty to the results (Sun et al., 2022a).

DFU is a prevalent and severe complication of diabetes, impacting skin, muscle, nerve, and vascular systems, thereby complicating the healing process (Sun et al., 2022b). The pathogenesis is driven by a high-sugar microenvironment that elevates oxidative stress, impairing wound healing (Patel et al., 2019). This environment also facilitates reactions between proteins and glucose, producing harmful byproducts that inhibit

Study	Treatment Control N Mean SD N Mean S	D	Mean Diff. with 95% Cl	Weight (%)
Adipose				
Han et al., 2010	26 33.8 11.6 26 42.1 9	5 —	-8.30 [ -14.06, -2.54]	14.22
Moon et al., 2019	22 40.8 5.3 17 51.2	5 -	-10.40 [ -13.67, -7.13]	14.77
Lonardi et al., 2019	57 84 42 57 84 3	0	0.00 [ -13.40, 13.40]	11.47
Heterogeneity: $\tau^2 = 1$	1.86, I <sup>2</sup> = 16.22%, H <sup>2</sup> = 1.19	•	-9.15 [ -12.56, -5.74]	
Test of $\theta_i = \theta_j$ : Q(2) =	= 2.39, p = 0.30			
Bone				
Zhang et al., 2007	31 28 3.5 30 40.6 4	2	-12.60 [ -14.54, -10.66]	14.95
Heterogeneity: $\tau^2 = 0$	$0.00, I^2 = .\%, H^2 = .$	•	-12.60 [ -14.54, -10.66]	
Test of $\theta_i = \theta_j$ : Q(0) =	= 0.00, p = .			
Others				
Lavery et al., 2014	50 42 14.1 47 69.5 3	8 –	-27.50 [ -31.67, -23.33]	14.60
Park et al., 2018	82 56 5 85 84 4	5	-28.00 [ -29.44, -26.56]	14.99
Heterogeneity: $\tau^2 = 0$	$0.00, I^2 = 0.00\%, H^2 = 1.00$	•	-27.95 [ -29.31, -26.58]	
Test of $\theta_i = \theta_j$ : Q(1) =	= 0.05, p = 0.82			
Umbilical cord		_		
Wang X et al., 2024	43 27.3 2.8 43 31.5 3	3	-4.20 [ -5.49, -2.91]	15.00
Heterogeneity: $\tau^2 = 0$ Test of $\theta_i = \theta_j$ : Q(0) =	0.00, 1 <sup>2</sup> = .%, H <sup>2</sup> = . = -0.00, p = .	•	-4.20 [ -5.49, -2.91]	
<b>Overall</b> Heterogeneity: $\tau^2 = 1$ Test of $\theta_i = \theta_i$ : Q(6) =	150.20, I <sup>2</sup> = 99.06%, H <sup>2</sup> = 106.07 = 636.43, p = 0.00	•	-13.44 [ -22.76, -4.13]	
Test of group differen	nces: Q <sub>b</sub> (3) = 630.86, p = 0.00	<del> </del>	<del></del>	
Random-effects DerSi	imonian-Laird model	-30 -20 -10 0	10	

cell proliferation and adversely affect vascular and neural functions (Davis et al., 2020). Furthermore, an environment rich in fats and glucose promotes inflammatory responses, reducing neutrophil chemotaxis and macrophage efficacy, and hindering the macrophage phenotype shift from M1 to M2 (Boniakowski et al., 2019; Parisi et al., 2018). These complex mechanisms contribute to the high recurrence and worsening of DFU, placing significant psychological and economic burdens on patients. Addressing these challenges is critical and enhancing the clinical cure rate and accelerating wound healing are priorities in diabetes research. While it has been noted that VEGF and fibroblast growth factor levels are comparable in peripheral and bone marrow-derived cells, levels of interleukin-1b and tumor necrosis factor are higher in peripheral blood, suggesting less efficacy of peripheral blood mononuclear cells compared to bone marrowderived cells (Iba et al., 2002).

Back to our findings, Peripheral Blood-derived stem cells might be particularly effective due to their high availability and the potential presence of a wide range of progenitor cells, which can contribute to enhanced angiogenesis and tissue regeneration (Rai et al., 2022). Adipose-derived stem cells, while also effective, contain a rich mix of regenerative factors and have been shown to promote wound healing through their anti-inflammatory properties and ability to enhance collagen deposition (Zhang et al., 2020). Bone-derived stem cells are well-noted for their osteogenic and chondrogenic potential but may offer slightly less efficacy in soft tissue regeneration compared to other cell sources (Polymeri et al., 2016). Umbilical cord-derived stem cells, due to their unique regenerative capabilities, including antiinflammatory, immunomodulatory, and tissue repair properties, show potential in the treatment of diabetic foot ulcers; however, the lack of standardized treatment protocols may result in variability in their efficacy (Yu et al., 2023). These findings underscore the importance of selecting an appropriate stem cell source based on the specific clinical aspects and healing requirements of diabetic foot ulcers. The choice of stem cell type should consider the wound environment, the patient's overall health status, and the specific healing mechanisms needed (Lopes et al., 2018).

In addition, although our study found that peripheral blood derived stem cells and bone derived stem cells showed the most favorable therapeutic effects at follow-up times of 3 months or less and 3 months or more, respectively, the small overall sample size may be an important influencing factor. For example, a 12-week trial

Study	T	reatme	ent SD	N	Contro	9 9		Mean Diff.	Weight
Bone	IN	wear	30	IN	Wearr	30		with 95% Ci	(70)
Luetal 2011	11	65	07	11	54	09	-	0.11 [ 0.04 0.18	1 26 76
Heterogeneity: $\tau^2 = 0.00 \ l^2 = \%$	н <sup>2</sup> =	.00	.07		.04	.00	-	0.11 [ 0.04, 0.18	1 20.70
Test of $\theta_1 = \theta_1$ : $Q(0) = 0.00$ , $p = 1.00$								0.11[ 0.04, 0.10	1
Peripheral blood									
Huang et al., 2005	14	.63	.25	14	.51	.28		0.12 [ -0.08, 0.32	5.32
Qzturk et al., 2012	20	.87	.24	20	.73	.28		0.14 [ -0.02, 0.30	7.54
Mohammadzadeh et al., 2013	7	.92	.15	14	.65	.25		0.27 [ 0.07, 0.47	5.04
Zhang et al., 2016	27	.86	.07	26	.81	.09	-	0.05 [ 0.01, 0.09	] 39.04
Heterogeneity: $\tau^2 = 0.00$ , $I^2 = 45$ .	56%,	$H^{2} = 1$	.84				-	0.11 [ 0.02, 0.21	]
Test of $\theta_i = \theta_j$ : Q(3) = 5.51, p = 0.	.14								
Umbilical cord									
Wang X et al., 2024	43	.87	.26	43	.75	.21		0.12 [ 0.02, 0.22	] 16.29
Heterogeneity: $\tau^2 = 0.00$ , $I^2 = .\%$ ,	$H^2 =$							0.12 [ 0.02, 0.22	]
Test of $\theta_i = \theta_j$ : Q(0) = -0.00, p = .									
Overall							•	0.10 0.05, 0.15	1
Heterogeneity: $\tau^2 = 0.00$ , $I^2 = 31$ .	13%,	$H^{2} = 1$	.45					-	
Test of $\theta_i = \theta_j$ : Q(5) = 7.26, p = 0.	.20								
Test of group differences: Q <sub>b</sub> (2) =	= 0.0	3, p = 0	.99						
							0 .2 .4	.6	

in Turkey used autologous peripheral blood mononuclear cell transplantation to treat DFU, with a cure rate 31 times higher than that of patients receiving standard treatment. However, the total number of patients was only 40 (Ozturk et al., 2012). Another study evaluated the effects of autologous bone marrow mononuclear cells and CD90<sup>+</sup> enriched tissue repair cells in treating DFU patients. The treatment effects of the two cell on ulcer healing rates were 54 times and 25 times higher than that of the control group, respectively, but the total sample size was only 24 (Kirana et al., 2012). In contrast, Lonardi et al.'s study included over 100 patients who received adipose-derived stem cell therapy, but the treatment effect in the intervention group was only four times higher than that of the control group (Lonardi et al., 2019). Additionally, we observed that umbilical cord-derived stem cells had a significant effect on wound healing rates. One study using umbilical cord mesenchymal stem cell transplantation in DFU patients found that the observation group had significantly shorter healing times and faster wound closure compared to the control group, with the healing rate approximately 14 times higher (He, 2014). These findings emphasize the need for more and larger sample size studies to confirm the potential of stem cells from various sources in treating DFU.

However, there are some limitations to our meta-analysis. First, the relatively small sample sizes may limit the applicability of our findings to larger, more diverse patient populations. Second, the inherent heterogeneity among the included studies, due to variations in stem cell sources, protocols,

wound environments, and patient demographics, could affect the generalizability of the findings. Although we employed a random-effects model to address this variability, the differences in study designs and treatment regimens across studies still pose a challenge in interpreting the pooled results uniformly. Third, the presence of publication bias, as indicated by the asymmetry in funnel plots and confirmed by the trim-and-fill method, suggests that smaller studies with negative results might be underrepresented in the literature, potentially skewing the efficacy estimates. Lastly, the quantitative analysis was limited to published studies; thus, unpublished data and ongoing research alter the effectiveness could and safety profiles presented.

Future research should prioritize understanding the mechanisms behind stem cell-mediated wound healing and how patient-specific factors like genetics and metabolic control influence treatment outcomes. Comparative studies are essential to determine the most effective sources and types of stem cells, while the development of standardized protocols for cell preparation and application will enhance treatment consistency and efficacy. Longitudinal studies should evaluate the long-term effects of therapy, and integration with other treatments could lead to comprehensive care strategies. Additionally, addressing regulatory, ethical, and economic issues will be crucial for facilitating clinical implementation and ensuring the therapy's cost-effectiveness compared to conventional treatments.

Study	Treat	ment	Cor	ntrol		O	dds Ra	atio	Weigh
Adipose	Tes	NO	res	NU		VII	11 9070		(70)
Uzun et al., 2021	1	9	2	8		0.44 [	0.03.	5.881	5.98
Heterogeneity: $\tau^2 = 0.00$ , $I^2 = .%$	$H^2 = .$					0.44 [	0.03,	5.88]	
Test of $\theta_i = \theta_j$ : Q(0) = -0.00, p =							,		
Bone									
Debin et al., 2008	0	22	3	20		0.13 [	0.01,	2.68]	4.36
Lu et al., 2011	0	18	6	31		0.13 [	0.01,	2.46]	4.63
Karina et al. 2012a	2	10	1	5		– 1.00 [	0.07,	13.87]	5.76
Dubsky et al. 2013a	2	14	10	10		0.14 [	0.03,	0.80]	13.45
Dubsky et al., 2014	5	26	10	13		0.25 [	0.07,	0.88]	24.98
Heterogeneity: $\tau^2 = 0.00$ , $I^2 = 0.00$	00%, H	<sup>2</sup> = 1.	00		•	0.23 [	0.10,	0.54]	
Test of $\theta_i = \theta_j$ : Q(4) = 1.79, p = 0	0.77							_	
Others									
Lavery et al., 2014	0	50	1	46		0.31 [	0.01,	7.72]	3.83
Heterogeneity: $\tau^2 = 0.00$ , $I^2 = .%$	$H^2 = .$					0.31 [	0.01,	7.72]	
Test of $\theta_i = \theta_j$ : Q(0) = -0.00, p =									
Peripheral blood									
Huang et al., 2005	0	23	5	19		0.08 [	0.00,	1.45]	4.56
Qzturk et al., 2012	3	17	5	15		0.53 [	0.11,	2.60]	15.75
Dubsky et al. 2013b	1	10	10	10		0.10 [	0.01,	0.93]	7.98
Mohammadzadeh et al., 2013	0	7	7	7		0.07 [	0.00,	1.39]	4.32
Zhang et al., 2016	0	27	3	23		0.12 [	0.01,	2.49]	4.39
Heterogeneity: $\tau^{2} = 0.00$ , $I^{2} = 0.00$	00%, H	<sup>2</sup> = 1.	00		-	0.19 [	0.07,	0.54]	
Test of $\theta_i = \theta_j$ : Q(4) = 2.83, p = 0	0.59					-		_	
Overall					•	0.22 [	0.12,	0.42]	
Heterogeneity: $\tau^2 = 0.00$ , $I^2 = 0.0$	00%, H	<sup>2</sup> = 1.	00		•		,		
Test of $\theta_i = \theta_j$ : Q(11) = 5.01, p =	0.93								
Test of group differences: $Q_b(3)$	= 0.39,	p = 0	).94		1 1 1	_			
andom-effects DerSimonian-La	ird mor	lel		1/	256 1/32 1/4 2				
	nu mot								

# Conclusion

This study shows that stem cell therapy may be a promising method to promote wound healing in patients with diabetes foot ulcers, but its effectiveness varies depending on the source of stem cells. Despite evidence of moderate heterogeneity and publication bias, this analysis demonstrates the overall effectiveness of stem cell therapy in improving clinical outcomes in DFU management.

# Author contributions

LeT: Formal Analysis, Project administration, Validation, Writing-original draft. LiT: Data curation, Investigation, Writing-review and editing. BT: Data curation, Writing-review and editing. JZ: Conceptualization, Methodology, Software, Supervision, Visualization, Writing-review and editing.

# Funding

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.

# **Conflict of interest**

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

# Generative AI statement

The author(s) declare that no Generative AI was used in the creation of this manuscript.

# Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

# References

Boniakowski, A. M., denDekker, A. D., Davis, F. M., Joshi, A., Kimball, A. S., Schaller, M., et al. (2019). SIRT3 regulates macrophage-mediated inflammation in diabetic wound repair. *J. Invest Dermatol* 139 (12), 2528–2537.e2. doi:10.1016/j.jid.2019.05.017

Chen, Y., Wang, Y., and Zhang, T. (2023). Efficacy of Chinese and western medical techniques in treating diabetic foot ulcers with necrotizing fasciitis of the lower leg. *Int. J. Low. Extrem Wounds* 23 (1), 70–79. doi:10.1177/15347346221150865

Dai, J., Jiang, C., Chen, H., and Chai, Y. (2020). Treatment of diabetic foot with autologous stem cells: a meta-analysis of randomized studies. *Stem Cells Int.* 2020, 6748530. doi:10.1155/2020/6748530

Davis, F. M., Tsoi, L. C., Wasikowski, R., denDekker, A., Joshi, A., Wilke, C., et al. (2020). Epigenetic regulation of the PGE2 pathway modulates macrophage phenotype in normal and pathologic wound repair. *JCI Insight* 5 (17), e138443. doi:10.1172/jci. insight.138443

Debin, L., Youzhao, J., Ziwen, L., Xiaoyan, L., Zhonghui, Z., and Bing, C. (2008). Autologous transplantation of bone marrow mesenchymal stem cells on diabetic patients with lower limb ischemia. *J. Med. Coll. PLA* 23 (2), 106–115. doi:10.1016/ s1000-1948(08)60031-3

Dubsky, M., Jirkovska, A., Bem, R., Fejfarova, V., Pagacova, L., Sixta, B., et al. (2013). Both autologous bone marrow mononuclear cell and peripheral blood progenitor cell therapies similarly improve ischaemia in patients with diabetic foot in comparison with control treatment. *Diabetes Metab. Res. Rev.* 29 (5), 369–376. doi:10.1002/dmrr.2399

Dubský, M., Jirkovská, A., Bem, R., Fejfarová, V., Pagacová, L., Nemcová, A., et al. (2014). Comparison of the effect of stem cell therapy and percutaneous transluminal angioplasty on diabetic foot disease in patients with critical limb ischemia. *Cytotherapy* 16 (12), 1733–1738. doi:10.1016/j.jcyt.2014.08.010

Edmonds, M., Manu, C., and Vas, P. (2021). The current burden of diabetic foot disease. J. Clin. Orthop. Trauma 17, 88–93. doi:10.1016/j.jcot.2021.01.017

Galindo, L. T., Filippo, T. R., Semedo, P., Ariza, C. B., Moreira, C. M., Camara, N. O. S., et al. (2011). Mesenchymal stem cell therapy modulates the inflammatory response in experimental traumatic brain injury. *Neurol. Res. Int.* 2011, 564089. doi:10.1155/2011/564089

Guo, J., Dardik, A., Fang, K., Huang, R., and Gu, Y. (2017). Meta-analysis on the treatment of diabetic foot ulcers with autologous stem cells. *Stem Cell Res. Ther.* 8 (1), 228. doi:10.1186/s13287-017-0683-2

Han, S. K., Kim, H. R., and Kim, W. K. (2010). The treatment of diabetic foot ulcers with uncultured, processed lipoaspirate cells: a pilot study. *Wound Repair Regen.* 18 (4), 342–348. doi:10.1111/j.1524-475X.2010.00593.x

He, Y. Q. (2014). Clinical research on the umbilical cord mesenchymal stem cells therapy in the treatment of type 2 diabetes skin ulcer. *Chin. J. Coal Ind. Med.* 17 (4), 532–534. doi:10.11723/mtgyyx.1007-9564.201404005

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

# Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fgene.2024.1541992/ full#supplementary-material

#### SUPPLEMENTARY FIGURE S1

L'Abbé plot for trials evaluating the impact of stem cells from different sources on the healing rate in DFU.

#### SUPPLEMENTARY FIGURE S2

Funnel plot of stem cells from different sources on the healing rate in DFU.

#### SUPPLEMENTARY FIGURE S3

Overall Funnel plot of stem cells on the healing rate in DFU.

#### SUPPLEMENTARY FIGURE S4

Sensitivity analysis of stem cells from different sources on the healing rate in DFU.

Huang, P., Li, S., Han, M., Xiao, Z., Yang, R., and Han, Z. C. (2005). Autologous transplantation of granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells improves critical limb ischemia in diabetes. *Diabetes Care* 28 (9), 2155–2160. doi:10.2337/diacare.28.9.2155

Humphries, M. D., Brunson, A., Li, C. S., Melnikow, J., and Romano, P. S. (2016). Amputation trends for patients with lower extremity ulcers due to diabetes and peripheral artery disease using statewide data. *J. Vasc. Surg.* 64 (6), 1747–1755.e3. doi:10.1016/j.jvs.2016.06.096

Iba, O., Matsubara, H., Nozawa, Y., Fujiyama, S., Amano, K., Mori, Y., et al. (2002). Angiogenesis by implantation of peripheral blood mononuclear cells and platelets into ischemic limbs. *Circulation* 106 (15), 2019–2025. doi:10.1161/01.cir.0000031332. 45480.79

Ibrahim, A. (2017). IDF clinical practice recommendation on the diabetic foot: a guide for healthcare professionals. *Diabetes Res. Clin. Pract.* 127, 285–287. doi:10.1016/j. diabres.2017.04.013

Jain, P., Perakath, B., Jesudason, M. R., and Nayak, S. (2011). The effect of autologous bone marrow-derived cells on healing chronic lower extremity wounds: results of a randomized controlled study. *Ostomy Wound Manage* 57 (7), 38–44.

Kirana, S., Stratmann, B., Prante, C., Prohaska, W., Koerperich, H., Lammers, D., et al. (2012). Autologous stem cell therapy in the treatment of limb ischaemia induced chronic tissue ulcers of diabetic foot patients. *Int. J. Clin. Pract.* 66 (4), 384–393. doi:10. 1111/j.1742-1241.2011.02886.x

Krasilnikova, O. A., Baranovskii, D. S., Lyundup, A. V., Shegay, P. V., Kaprin, A. D., and Klabukov, I. D. (2022). Stem and somatic cell monotherapy for the treatment of diabetic foot ulcers: review of clinical studies and mechanisms of action. *Stem Cell Rev. Rep.* 18 (6), 1974–1985. doi:10.1007/s12015-022-10379-z

Lavery, L. A., Fulmer, J., Shebetka, K. A., Regulski, M., Vayser, D., Fried, D., et al. (2014). The efficacy and safety of  $Grafix(^{\textcircled{m}})$  for the treatment of chronic diabetic foot ulcers: results of a multi-centre, controlled, randomised, blinded, clinical trial. *Int. Wound J.* 11 (5), 554–560. doi:10.1111/iwj.12329

Lipsky, B. A., Senneville, É., Abbas, Z. G., Aragón-Sánchez, J., Diggle, M., Embil, J. M., et al. (2020). Guidelines on the diagnosis and treatment of foot infection in persons with diabetes (IWGDF 2019 update). *Diabetes Metab. Res. Rev.* 36 (Suppl. 1), e3280. doi:10. 1002/dmrr.3280

Liu, Y., He, L., Cheng, L., Li, X., Gao, M., Li, Q., et al. (2023a). Enhancing bone grafting outcomes: A. Comprehensive review of antibacterial artificial composite bone scaffolds. *Med. Sci. Monit.* 29, e939972. doi:10.12659/MSM.939972

Liu, P. Y., Ma, H. W., and Zhang, Y. Q. (2023b). Effect of autologous bone marrow stem cell transplantation on diabetic foot. *Hebei Med. J.* 45 (4), 579–581. doi:10.3969/j. issn.1002-7386.2023.04.025

Lonardi, R., Leone, N., Gennai, S., Trevisi Borsari, G., Covic, T., and Silingardi, R. (2019). Autologous micro-fragmented adipose tissue for the treatment of diabetic foot minor amputations: a randomized controlled single-center clinical trial (MiFrAADiF). *Stem Cell Res. Ther.* 10 (1), 223. doi:10.1186/s13287-019-1328-4

Lopes, L., Setia, O., Aurshina, A., Liu, S., Hu, H., Isaji, T., et al. (2018). Stem cell therapy for diabetic foot ulcers: a review of preclinical and clinical research. *Stem Cell Res. Ther.* 9 (1), 188. doi:10.1186/s13287-018-0938-6

Lu, D., Chen, B., Liang, Z., Deng, W., Jiang, Y., Li, S., et al. (2011). Comparison of bone marrow mesenchymal stem cells with bone marrow-derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: a double-blind, randomized, controlled trial. *Diabetes Res. Clin. Pract.* 92 (1), 26–36. doi:10.1016/j.diabres.2010. 12.010

Meloni, M., Izzo, V., Da Ros, V., Morosetti, D., Stefanini, M., Brocco, E., et al. (2020). Characteristics and outcome for persons with diabetic foot ulcer and No-option critical limb ischemia. *J. Clin. Med.* 9 (11), 3745. doi:10.3390/jcm9113745

Mimeault, M., Hauke, R., and Batra, S. K. (2007). Stem cells: a revolution in therapeutics-recent advances in stem cell biology and their therapeutic applications in regenerative medicine and cancer therapies. *Clin. Pharmacol. Ther.* 82 (3), 252–264. doi:10.1038/sj.clpt.6100301

Mohammadzadeh, L., Samedanifard, S. H., Keshavarzi, A., Alimoghaddam, K., Larijani, B., Ghavamzadeh, A., et al. (2013). Therapeutic outcomes of transplanting autologous granulocyte colony-stimulating factor-mobilised peripheral mononuclear cells in diabetic patients with critical limb ischaemia. *Exp. Clin. Endocrinol. Diabetes* 121 (1), 48–53. doi:10.1055/s-0032-1311646

Moon, K. C., Suh, H. S., Kim, K. B., Han, S. K., Young, K. W., Lee, J. W., et al. (2019). Potential of allogeneic adipose-derived stem cell-hydrogel complex for treating diabetic foot ulcers. *Diabetes* 68 (4), 837–846. doi:10.2337/db18-0699

Mrozikiewicz-Rakowska, B., Szabłowska-Gadomska, I., Cysewski, D., Rudziński, S., Płoski, R., Gasperowicz, P., et al. (2023). Allogenic adipose-derived stem cells in diabetic foot ulcer treatment: clinical effectiveness, safety, survival in the wound site, and proteomic impact. *Int. J. Mol. Sci.* 24 (2), 1472. doi:10.3390/ijms24021472

Ozturk, A., Kucukardali, Y., Tangi, F., Erikci, A., Uzun, G., Bashekim, C., et al. (2012). Therapeutical potential of autologous peripheral blood mononuclear cell transplantation in patients with type 2 diabetic critical limb ischemia. *J. Diabetes Complicat.* 26 (1), 29–33. doi:10.1016/j.jdiacomp.2011.11.007

Parisi, L., Gini, E., Baci, D., Tremolati, M., Fanuli, M., Bassani, B., et al. (2018). Macrophage polarization in chronic inflammatory diseases: killers or builders? J. Immunol. Res. 2018, 8917804. doi:10.1155/2018/8917804

Park, K. H., Han, S. H., Hong, J. P., Han, S. K., Lee, D. H., Kim, B. S., et al. (2018). Topical epidermal growth factor spray for the treatment of chronic diabetic foot ulcers: a phase III multicenter, double-blind, randomized, placebo-controlled trial. *Diabetes Res. Clin. Pract.* 142, 335–344. doi:10.1016/j.diabres.2018.06.002

Patel, S., Srivastava, S., Singh, M. R., and Singh, D. (2019). Mechanistic insight into diabetic wounds: pathogenesis, molecular targets and treatment strategies to pace wound healing. *Biomed. Pharmacother.* 112, 108615. doi:10.1016/j.biopha. 2019.108615

Polymeri, A., Giannobile, W. V., and Kaigler, D. (2016). Bone marrow stromal stem cells in tissue engineering and regenerative medicine. *Horm. Metab. Res.* 48 (11), 700–713. doi:10.1055/s-0042-118458

Rai, V., Moellmer, R., and Agrawal, D. K. (2022). Stem cells and angiogenesis: implications and limitations in enhancing chronic diabetic foot ulcer healing. *Cells* 11 (15), 2287. doi:10.3390/cells11152287

Sasaki, M., Abe, R., Fujita, Y., Ando, S., Inokuma, D., and Shimizu, H. (2008). Mesenchymal stem cells are recruited into wounded skin and contribute to wound repair by transdifferentiation into multiple skin cell type. J. Immunol. 180 (4), 2581-2587. doi:10.4049/jimmunol.180.4.2581

Singh, G. D., Brinza, E. K., Hildebrand, J., Waldo, S. W., Foley, T. R., Laird, J. R., et al. (2017). Midterm outcomes after infrapopliteal interventions in patients with critical limb ischemia based on the TASC II classification of below-the-knee arteries. *J. Endovasc. Ther.* 24 (3), 321–330. doi:10.1177/1526602817704643

Smith, O. J., Leigh, R., Kanapathy, M., Macneal, P., Jell, G., Hachach-Haram, N., et al. (2020). Fat grafting and platelet-rich plasma for the treatment of diabetic foot ulcers: a feasibility-randomised controlled trial. *Int. Wound J.* 17 (6), 1578–1594. doi:10.1111/iwj.13433

Sun, Y., Zhao, J., Zhang, L., Li, Z., and Lei, S. (2022a). Effectiveness and safety of stem cell therapy for diabetic foot: a meta-analysis update. *Stem Cell Res. Ther.* 13 (1), 416. doi:10.1186/s13287-022-03110-9

Sun, H., Saeedi, P., Karuranga, S., Pinkepank, M., Ogurtsova, K., Duncan, B. B., et al. (2022b). IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. *Diabetes Res. Clin. Pract.* 183, 109119. doi:10.1016/j.diabres.2021.109119

Tutuianu, R., Rosca, A. M., Iacomi, D. M., Simionescu, M., and Titorencu, I. (2021). Human mesenchymal stromal cell-derived exosomes promote *in vitro* wound healing by modulating the biological properties of skin keratinocytes and fibroblasts and stimulating angiogenesis. *Int. J. Mol. Sci.* 22 (12), 6239. doi:10.3390/ijms22126239

Uzun, E., Güney, A., Gönen, Z. B., Özkul, Y., Kafadar, İ. H., Günay, M., et al. (2021). Intralesional allogeneic adipose-derived stem cells application in chronic diabetic foot ulcer: phase I/2 safety study. *Foot Ankle Surg.* 27 (6), 636–642. doi:10.1016/j.fas.2020. 08.002

Wang, X. F., Gao, S. W., and Zhang, Z. (2024a). The curative effect of umbilical cord mesenchymal stem cells transplantation combined with vacuum sealing drainage for diabetic foot ulcer. *Anhui Med. Pharm. J.* 28 (4), 777–781. doi:10.3969/j.issn.1009-6469. 2024.04.030

Wang, G. Y., Li, Q. Y., and Jia, Y. P. (2024b). Therapeutic effect of peripheral blood stem cells combined with exosomes on diabetic foot ulcer wounds. *Chin. J. Aesthet. Med.* 33 (8), 33–37.

Weledji, E. P., and Fokam, P. (2014). Treatment of the diabetic foot - to amputate or not? *BMC Surg.* 14, 83. doi:10.1186/1471-2482-14-83

Xia, Y., Wu, P., Chen, H., and Chen, Z. (2024). Advances in stem cell therapy for diabetic foot. *Front. Genet.* 15, 1427205. doi:10.3389/fgene.2024.1427205

You, H. J., Han, S. K., Lee, J. W., and Chang, H. (2012). Treatment of diabetic foot ulcers using cultured allogeneic keratinocytes--a pilot study. *Wound Repair Regen.* 20 (4), 491–499. doi:10.1111/j.1524-475X.2012.00809.x

Yu, Q., Qiao, G. H., Wang, M., Yu, L., Sun, Y., Shi, H., et al. (2022). Stem cell-based therapy for diabetic foot ulcers. *Front. Cell Dev. Biol.* 10, 812262. doi:10.3389/fcell.2022. 812262

Yu, X., Liu, P., Li, Z., and Zhang, Z. (2023). Function and mechanism of mesenchymal stem cells in the healing of diabetic foot wounds. *Front. Endocrinol. (Lausanne)* 14, 1099310. doi:10.3389/fendo.2023.1099310

Zhang, Z., Liu, W. S., and Zhao, X. L. (2007). Autologous bone marrow stem cell transplantation for treatment of diabetes foot ulcer. *Prac. Clin. Med.* 8 (8), 58–60.

Zhang, X., Lian, W., Lou, W., Han, S., Lu, C., Zuo, K., et al. (2016). Transcatheter arterial infusion of autologous CD133(+) cells for diabetic peripheral artery disease. *Stem Cells Int.* 2016, 6925357. doi:10.1155/2016/6925357

Zhang, J., Liu, Y., Chen, Y., Yuan, L., Liu, H., Wang, J., et al. (2020). Adipose-derived stem cells: current applications and future directions in the regeneration of multiple tissues. *Stem Cells Int.* 2020, 8810813. doi:10.1155/2020/8810813